

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2021 OF THE CONDITION AND AFFAIRS OF THE

AMH Health, LLC

N	IAIC Group Code 0671 NAIC (Current) (Prior)	Company Code1655	Employer's ID Nu	umber <u>83-2435050</u>
Organized under the Laws		, State of Do	micile or Port of Entry	ME
Country of Domicile		United States of America		
Licensed as business type	e: <u>Hea</u>	alth Maintenance Organiza	ation	
Is HMO Federally Qualifie	ed? Yes [] No [X]			
Incorporated/Organized _	11/02/2018	Comme	nced Business	04/12/2019
Statutory Home Office	2 Gannett Drive			th Portland, ME, US 04106
	(Street and Number)		(City or To	wn, State, Country and Zip Code)
Main Administrative Office		4425 Corporation Lane		
	Virginia Beach, VA, US 23462	(Street and Number)		757-473-2737
(Ci	ty or Town, State, Country and Zip Code)		(Area	Code) (Telephone Number)
Mail Address	4425 Corporation Lane		Virc	jinia Beach, VA, US 23462
- Mail Address	(Street and Number or P.O. Box)			wn, State, Country and Zip Code)
Primary Location of Books	e and Becorde	220 Virginia Avenue		
Filliary Location of Books	s and Records	(Street and Number)		
	Indianapolis, IN, US 46204			317-488-6000
(Ci	ty or Town, State, Country and Zip Code)		(Area	Code) (Telephone Number)
Internet Website Address	www.ar	nthem.com/medicare-mair	nehealth	
Statutory Statement Cont	act Leigh Barrett			317-488-6816
•	(Name)		(Area Code) (Telephone Number)
-	leigh.barrett@anthem.com (E-mail Address)			317-488-6200 (FAX Number)
	(E-mail Address)			(I AX Number)
	- 10 W	OFFICERS		
President and Chairpers	on Raul Guillermo Smith ary Kathleen Susan Kiefer		Treasurer stant Treasurer	
0001010	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
		OTHER		
		ECTORS OR TRUSTE		
	sey Furman #	Douglas Jay Johnson		Scott Douglas Mills
	George McGinty id Earl Warren	Raul Guillermo Smith		Albert Graton Swallow III
State of	Indiana			
County of	Johnson SS			
The officers of this reporti	ing entity being duly sworn, each depose and say th	nat they are the described	officers of said reporting	ng entity, and that on the reporting period stated above,
				claims thereon, except as herein stated, and that this true statement of all the assets and liabilities and of the
condition and affairs of the	e said reporting entity as of the reporting period star	ted above, and of its incor	me and deductions the	erefrom for the period ended, and have been completed
				e extent that: (1) state law may differ; or, (2) that state the best of their information, knowledge and belief,
respectively. Furthermore	e, the scope of this attestation by the described off	ficers also includes the re	lated corresponding el	lectronic filing with the NAIC, when required, that is an
to the enclosed statement		DocuSigned by:	lectronic filing may be	requested by various regulators in lieu of or in addition — DocuSigned by:
Smith	i, Raul Guillermo	Hattry Kieler		Vincent E. Scher
73943	E4C5BB8409	4 /***) - 1	ev	
Raul Guille Presi		Kathleen Susan Kiefer Secretary		Vincent Edward Scher Treasurer
11.00 Tab	90000000A	STREET STREET		embos#575% মার্কিরার
		a. Ist	this an original filing?	Yes[X] No[]
Subscribed and sworn to		b. If n	10,	
	y of		State the amendment	
Pitant Sente	8		Date filed Number of pages attac	
Rita F. Gentry Executive Assistant			, 3	
1/17/2029				

Rita F. Gentry
Notary Public
SEAL
Johnson County
My Commission Expires January 17, 2029
Commission No: NP0641321

	ANNUAL STATEMENT FOR THE	SETS		- ,	
			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	27,016,024			119,484
2.	Stocks (Schedule D):			, ,	
	2.1 Preferred stocks			0	0
	2.2 Common stocks	3,936,356		3,936,356	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens			0	0
	3.2 Other than first liens			0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)			0	0
	4.2 Properties held for the production of income (less				
	\$ encumbrances)			0	0
	4.3 Properties held for sale (less \$ encumbrances)			0	0
5.	Cash (\$69,499,398 , Schedule E - Part 1), cash equivalents				
-	(\$, Schedule E - Part 2) and short-term				
	investments (\$, Schedule DA)	69,499,398		69,499,398	50,453,932
6.	Contract loans, (including \$ premium notes)				
7.	Derivatives (Schedule DB)				
8.	Other invested assets (Schedule BA)				
9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)	1,561,239		1,561,239	0
11.	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)				
13.	Title plants less \$ charged off (for Title insurers				
	only)			0	0
14.	Investment income due and accrued	7,210		7,210	3,333
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection.	202,917	59,437	143,480	60,377
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$				
	earned but unbilled premiums)			0	0
	15.3 Accrued retrospective premiums (\$				
	contracts subject to redetermination (\$4,378,372)	4,378,372		4,378,372	1,051,966
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers				0
	16.2 Funds held by or deposited with reinsured companies				0
	16.3 Other amounts receivable under reinsurance contracts				0
17.	Amounts receivable relating to uninsured plans			, , , , , , , , , , , , , , , , , , ,	606,446
18.1	Current federal and foreign income tax recoverable and interest thereon			· · · · · · · · · · · · · · · · · · ·	479,764
	Net deferred tax asset			,	244,778
19.	Guaranty funds receivable or on deposit				0
20.	Electronic data processing equipment and software			0	0
21.	Furniture and equipment, including health care delivery assets (\$			_	n
22.	Net adjustment in assets and liabilities due to foreign exchange rates				0
23.	Receivables from parent, subsidiaries and affiliates				0
24.	Health care (\$2,125,937) and other amounts receivable			2,125,937	
25.	Aggregate write-ins for other than invested assets			969,934	
26.	Total assets excluding Senarate Accounts Segregated Accounts and			,	,
27.	Protected Cell Accounts (Lines 12 to 25) From Separate Accounts, Segregated Accounts and Protected Cell	114,263,150	479,741	113,783,409	54,566,885
28.	Accounts	114,263,150	479,741	113,783,409	0 54,566,885
	DETAILS OF WRITE-INS	, , , ,	- /	-, -, -,	
1101.					
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page		0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0	0
2501.	State income tax recoverable	969,934	0	969,934	146,210
2502.	Prepaid expenses		257, 109	0	0
2503.	' '				
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0		0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	1,227,043	257, 109	969,934	146,210

LIABILITIES, CAPITAL AND SURPLUS

	LIABILITIES, CAP	, ,	Current Year		Prior Year
	ļ	1	2	3	4
		Covered	Uncovered	Total	Total
1. (Claims unpaid (less \$0 reinsurance ceded)				12,515,810
	Accrued medical incentive pool and bonus amounts				
	Jnpaid claims adjustment expenses				263,115
	Aggregate health policy reserves, including the liability of	, ,		,,	, ,
	\$0 for medical loss ratio rebate per the Public				
	Health Service Act	1.235.861		1.235.861	9.755
	Aggregate life policy reserves				0
	Property/casualty unearned premium reserves.				
	Aggregate health claim reserves				
	Premiums received in advance				
	General expenses due or accrued.				
	Current federal and foreign income tax payable and interest thereon	,,,,,		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	, , , , , , , , , , , , , , , , , , , ,
	(including \$ on realized capital gains (losses))			0	0
	Net deferred tax liability				0
	Ceded reinsurance premiums payable				
	Amounts withheld or retained for the account of others				
	Remittances and items not allocated.				
	Borrowed money (including \$ current) and	,		,	
	interest thereon \$(including				
	\$ current)			0	0
	Amounts due to parent, subsidiaries and affiliates				
	Derivatives.	· · ·			0
	Payable for securities				0
	Payable for securities lending				0
	Funds held under reinsurance treaties (with \$	1,001,200		1,001,200	
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$			0	0
	Reinsurance in unauthorized and certified (\$				
	companies			0	0
	Net adjustments in assets and liabilities due to foreign exchange rates				0
	Liability for amounts held under uninsured plans				1.218
	Aggregate write-ins for other liabilities (including \$	40,302		40,302	1,210
	current)	156 637	0	156 637	48 800
	Fotal liabilities (Lines 1 to 23)				
	Aggregate write-ins for special surplus funds.				
	Common capital stock.				
	Preferred capital stock				
	Gross paid in and contributed surplus				
	Surplus notes				
	Aggregate write-ins for other than special surplus funds				
	Jnassigned funds (surplus)				
	- ' ' '			(0,200,293)	(3,900,172)
	Less treasury stock, at cost:				
3	32.1shares common (value included in Line 26	2004	2004		
_	\$	XXX	XXX		
3		VVV	VVV		
00 -	\$				1/ 101 020
	Fotal liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	113,783,409	54,566,885
	DETAILS OF WRITE-INS	440 404		440 404	45.04
	Niscellaneous Medicare liabilities				
	Scheat liability				3,273
2303					
	Summary of remaining write-ins for Line 23 from overflow page				0
	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	156,637	0	156,637	48,890
2598.	Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX		0
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
3002		xxx	xxx		
3098.	Summary of remaining write-ins for Line 30 from overflow page	xxx	XXX	0	0
3099.	Fotals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	xxx	0	0

STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AN	Current \		Prior Year
		1	2	3
		Uncovered	Total	Total
1.	Member Months	XXX	160,585	69,079
2.	Net premium income (including \$ non-health premium income)	XXX	170,491,948	76,123,555
3.	Change in unearned premium reserves and reserve for rate credits	XXX	(1,227,969)	(7,892)
	Fee-for-service (net of \$ medical expenses)			
	Risk revenue			0
	Aggregate write-ins for other health care related revenues			0
	Aggregate write-ins for other non-health revenues			
8.	Total revenues (Lines 2 to 7)	XXX	169,263,979	76,115,663
	Hospital and Medical:			
	Hospital/medical benefits			
10.	Other professional services		13,994,942	5,909,233
11.	Outside referrals		0	0
12.	Emergency room and out-of-area		8,178,282	3,084,288
13.	Prescription drugs		10.418.480	5.394.786
	Aggregate write-ins for other hospital and medical.			0
	Incentive pool, withhold adjustments and bonus amounts			
16.	Subtotal (Lines 9 to 15)	0	149,478,903	64,029,638
	Less:			
	Net reinsurance recoveries			
18.	Total hospital and medical (Lines 16 minus 17)	0	149,478,903	64,029,638
19.	Non-health claims (net)			
20.	Claims adjustment expenses, including \$		8,378,491	2,903,480
	General administrative expenses			
	Increase in reserves for life and accident and health contracts (including \$			
22.	, ,		0	0
	increase in reserves for life only)			
	Total underwriting deductions (Lines 18 through 22)			
24.	Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	(6,295,133)	(749,634)
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)		259,088	(10,181)
26.	Net realized capital gains (losses) less capital gains tax of \$		152,510	0
27.	Net investment gains (losses) (Lines 25 plus 26)	0	411,598	(10, 181)
	Net gain or (loss) from agents' or premium balances charged off [(amount recovered		,	
20.			(0.097)	(2.752)
	7.			
29.	Aggregate write-ins for other income or expenses	0	58 , 133	39,585
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	>>>	(5 835 380)	(722,983)
	Federal and foreign income taxes incurred			
32.	Net income (loss) (Lines 30 minus 31)	XXX	(5,823,045)	(981,719)
	DETAILS OF WRITE-INS			
0601.		xxx		
0602.		XXX		
0603		XXX		
0698.	Summary of remaining write-ins for Line 6 from overflow page	xxx	0	0
	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.	(
0701.		XXX		
0702.				
				Λ
	Summary of remaining write-ins for Line 7 from overflow page		0	0
	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX		0
1401.				
_				
1403.				
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901.	Miscellaneous income (expense)		58 , 133	39,585
2902.				
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page	0	0	0
	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	58,133	39,585

STATEMENT OF REVENUE AND EXPENSES (Continued)

	STATEMENT OF REVENUE AND EXPENSES	(Continued)	
		1 Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
	VALUE AND SUM ESS ASSOCIAT		
33.	Capital and surplus prior reporting year.	14 101 828	6 355 068
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves		
33.			
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$		
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax	(25,232)	257,830
39.	Change in nonadmitted assets	2,390,054	(2,869,607
40	Change in unauthorized and certified reinsurance	0	
41.	Change in treasury stock	0	
42.	Change in surplus notes	0	C
43.	Cumulative effect of changes in accounting principles		
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	
	44.3 Transferred to surplus.		
45.	Surplus adjustments:		
	45.1 Paid in	21,000,000	11,502,000
	45.2 Transferred to capital (Stock Dividend)		
	45.3 Transferred from capital		
46.	Dividends to stockholders		
47.	Aggregate write-ins for gains or (losses) in surplus	0	0
48.	Net change in capital and surplus (Lines 34 to 47)		7,746,760
49.	Capital and surplus end of reporting period (Line 33 plus 48)	30,741,705	14,101,828
	DETAILS OF WRITE-INS		
4701.			
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page		·
		0	
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	U	

CASH FLOW

	0/(0/17 2017	1	2
			_
		Current Year	Prior Year
	Cash from Operations	407,000,470	75 040 000
1.	Premiums collected net of reinsurance		
2.	Net investment income		(6,940)
3.	Miscellaneous income		0
4.	Total (Lines 1 through 3)		75,005,362
5.	Benefit and loss related payments		52,447,870
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions		
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$		699,999
10.	Total (Lines 5 through 9)	168,127,454	63,841,065
11.	Net cash from operations (Line 4 minus Line 10)	(676,319)	11,164,297
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
12.	12.1 Bonds	35 126 183	n
	12.2 Stocks	, ,	0
	12.3 Mortgage loans		0
	12.4 Real estate		0
	12.5 Other invested assets		0
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
			0
	12.7 Miscellaneous proceeds		0
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	35, 126, 183	0
13.	Cost of investments acquired (long-term only):	00.007.000	0
	13.1 Bonds		
	13.2 Stocks	, ,	, ,
	13.3 Mortgage loans		0
	13.4 Real estate		0
	13.5 Other invested assets		
	13.6 Miscellaneous applications	1,561,239	0
	13.7 Total investments acquired (Lines 13.1 to 13.6)	66,168,439	2,400,000
14.	Net increase (decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(31,042,256)	(2,400,000)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock	21,000,000	11,502,000
	16.3 Borrowed funds	0	0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		0
	16.5 Dividends to stockholders		
	16.6 Other cash provided (applied)		23,636,772
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)		35,138,772
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	10 0:- :	10.000.000
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	19,045,466	43,903,069
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year		6,550,863
	19.2 End of year (Line 18 plus Line 19.1)	69,499,398	50,453,932

Note: Supplemental disclosures of cash flow information for non-cash transactions:	

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

	_						OL DOSINI				
		1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
			Comprehensive	Medicare	Dental	Vision	Health	XVIII	XIX		Other
		Total	(Hospital & Medical)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
1.		170,491,948						170,491,948			
2.	Change in unearned premium reserves and reserve for rate credit	(1,227,969)						(1,227,969)			
3.	Fee-for-service (net of \$										
	medical expenses)	0									XXX
4.	Risk revenue	0									XXX
5.	Aggregate write-ins for other health care related revenues	0	0	0	0	0	0	0	0	0	XXX
6.	Aggregate write-ins for other non-health care related revenues	0	xxx	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
7.	Total revenues (Lines 1 to 6)	169,263,979	Λ					169,263,979			
8.	Hospital/medical benefits	114,480,733	u	υ	νυ	u		114,480,733	u	ν	XXX
9.	Other professional services	114,480,733						13,994,942			XXX
								13,994,942			XXX
10.	Outside referrals Emergency room and out-of-area	0						0.470.000			
11.		8, 178, 282						8,178,282			XXX
12.	Prescription drugs	10,418,480						10,418,480			XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	2,406,466						2,406,466			XXX
15.	Subtotal (Lines 8 to 14)	149,478,903	0	0	0	0	Ω	149,478,903	0	0	XXX
16.	Net reinsurance recoveries	0									XXX
17.	Total medical and hospital (Lines 15 minus 16)	149,478,903	0	0	0	0	0	149,478,903	0	0	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
19.	Claims adjustment expenses including \$5,177,503 cost containment expenses	8,378,491						8.378.491			
20.	General administrative expenses	17,701,718						17,701,718			
21.	Increase in reserves for accident and health contracts	0									XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	Total underwriting deductions (Lines 17 to 22)	175,559,112	0	n	Λ	1		175.559.112	Λ	0	(
	Total underwriting gain or (loss) (Line 7 minus Line 23)	(6,295,133)	0	n	ر ۱	0	0	(6.295.133)		Λ	
	DETAILS OF WRITE-INS	(0,230, 100)		Ů	0			(0,293,133)	0	0	
											XXX
0502.											XXX
0503.											XXX
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	xxx
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	XXX
0601.	, , , , , , , , , , , , , , , , , , , ,		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	,
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
1301.											XXX
1302.						<u> </u>					XXX
1303.						<u> </u>					XXX
	Summary of remaining write-ins for Line 13 from overflow page	0	٥	n	0	0	n	0	n	n	XXX
1	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	n	ر ۱	0	0	0	0	0	XXX

7

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

FACT 1 - FACINIONIS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical)				0
Medicare Supplement				0
3. Dental only				0
4. Vision only				0
5. Federal Employees Health Benefits Plan	0			0
6. Title XVIII - Medicare	170,491,948			170,491,948
7. Title XIX - Medicaid	0			0
8. Other health				0
9. Health subtotal (Lines 1 through 8)	170,491,948	0		170,491,948
10. Life	0			0
11. Property/casualty	0			0
12. Totals (Lines 9 to 11)	170,491,948	0	0	170,491,948

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

					IMS INCURRED DU	RING THE TEAR	1				
		1	2	3	4	5	6 Federal	7	8	9	10
		Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1.	Payments during the year:										
	1.1 Direct	134,738,175						134,738,175			
	1.2 Reinsurance assumed	0									
	1.3 Reinsurance ceded	0									
	1.4 Net	134,738,175	0	0	0	0	0	134,738,175	0	0	(
2.	Paid medical incentive pools and bonuses	2.333.004						2,333,004			
	Claim liability December 31, current year from Part 2A:	, ,						, ,			
	3.1 Direct	25,907,920	0	0	0	0	0	25,907,920	0	0	(
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	(
	3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	(
	3.4 Net	25,907,920	0	0	0	0	0	25,907,920	0	0	(
4.	Claim reserve December 31, current year from Part 2D:	0									
	4.1 Direct										
	4.2 Reinsurance assumed										
	4.3 Reinsurance ceded										
	4.4 Net	0	0	0	0	0	0	0	0	0	(
	Accrued medical incentive pools and bonuses, current year	350,039						350,039			
6.	Net healthcare receivables (a)	1,057,848						1,057,848			
	Amounts recoverable from reinsurers December 31, current year	0									
8.	Claim liability December 31, prior year from Part 2A:										
	8.1 Direct	12,515,810	0	0	0	0	0	12,515,810	0	0	(
	8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	(
	8.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	(
	8.4 Net	12,515,810	0	0	0	0	0	12,515,810	0	0	(
	Claim reserve December 31, prior year from Part 2D: 9.1 Direct	0	0	0	0	0	0	0	0	0	(
	9.2 Reinsurance assumed	n							n		
	9.3 Reinsurance ceded	n l	0	0	n	n	0	n	n	n	(
	9.4 Net	n l	n	 n l	n		n	o	n)
	Accrued medical incentive pools and bonuses, prior year	276,577	n		n	n	n	276,577	n		
	Amounts recoverable from reinsurers December 31,	210,311	0	0	0	0	0	210,311	0	0	
	prior year	0	0	0	U	0	0	0	0	0	
	12.1 Direct	147,072,437	0		0	0	0	147,072,437	0	0	(
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	(
	12.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	(
	12.4 Net	147,072,437	0	0	0	0	0	,	0	0	(
13.	Incurred medical incentive pools and bonuses	2,406,466	0	0	0	0	0	2,406,466	0	0	

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

				O 217 (B1211 1 211B)	JI CONNENT ILAN					
	1	2 Comprehensive	3 Medicare	4	5	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	XVIII Medicare	XIX Medicaid	Other Health	Other Non-Health
Reported in Process of Adjustment:										
1.1 Direct	14,194,598						14,194,598			
1.2 Reinsurance assumed	0									
1.3 Reinsurance ceded	0									
1.4 Net	14,194,598	0	0	0	0	0	14, 194,598	0	0	0
Incurred but Unreported:										
2.1 Direct	11,713,322						11,713,322			
2.2 Reinsurance assumed	0									
2.3 Reinsurance ceded	0									
2.4 Net	11,713,322	0	0	0	0	0	11,713,322	0	0	0
Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	0									
3.2 Reinsurance assumed	0									
3.3 Reinsurance ceded	0									
3.4 Net	0	0	0	0	0	0	0	0	0	0
4. TOTALS:										
4.1 Direct	25,907,920	0	0	0	0	0	25,907,920	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	25,907,920	0	0	0	0	0	25,907,920	0	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

PART 2D - ANALTSIS OF CLAIMS UNPAID - PRI		Ouring the Year	Claim Reserve a	and Claim Liability	5	6
	1	2	3	4		Estimated Claim
	On Claims Incurred Prior to January 1	On Claims Incurred	On Claims Unpaid December 31 of	On Claims Incurred	Claims Incurred In Prior Years	Reserve and Claim Liability December 31 of
Line of Business	of Current Year	During the Year	Prior Year	During the Year	(Columns 1 + 3)	Prior Year
Comprehensive (hospital and medical)					0	0
2. Medicare Supplement					0	0
3. Dental Only					0	0
4. Vision Only					0	0
Federal Employees Health Benefits Plan					0	0
6. Title XVIII - Medicare	9,837,314	126,111,481	221,281	25,686,639	10,058,595	12,515,810
7 Title XIX - Medicaid					0	0
8. Other health					0	0
9. Health subtotal (Lines 1 to 8)	9,837,314	126,111,481	221,281	25,686,639	10,058,595	12,515,810
10. Healthcare receivables (a)	618	2,267,850			618	0
11. Other non-health					0	0
12. Medical incentive pools and bonus amounts	475,203	1,857,801	25,855	324 , 184	501,058	276,577
13. Totals (Lines 9 - 10 + 11 + 12)	10,311,899	125,701,432	247, 136	26,010,823	10,559,035	12,792,387

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

	Cumulative Net Amounts Paid					
	1	2	3	4	5	
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021	
1. Prior	0	0	0	0		
2. 2017						
3. 2018	XXX					
4. 2019	XXX	XXX				
5. 2020	XXX	XXX	XXX	51,237	61,549	
6. 2021	XXX	XXX	XXX	XXX	125,701	

Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bond Outstanding at End of Year				
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior	0	0	0	0	
2. 2017					
3. 2018	XXX				
4. 2019	XXX	XXX			
5. 2020	XXX	XXX	XXX	64,030	61,796
6. 2021	XXX	XXX	XXX	XXX	151,712

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017				0.0	0	0.0			0	0.0
2.	2018				0.0	0	0.0			0	0.0
3.	2019				0.0	0	0.0			0	0.0
4.	2020	76,116	61,549	3,229	5.2	64,778	85.1	247	4	65,029	85.4
5.	2021	169,264	125,701	7,552	6.0	133,253	78.7	26,011	496	159,760	94.4

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

	COOLON A T AIR TICATAL TOTAL	Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021			
1.	Prior	0	0	0	0	0			
2.	2017	0	0	0	0	0			
3.	2018	XXX	0	0	0	0			
4.	2019	XXX	XXX	0	0	0			
5.	2020	XXX	XXX	XXX	51,237	61,549			
6.	2021	XXX	XXX	XXX	XXX	125,701			

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net	: Amount Paid and C	laim Liability, Claim Rese Outstanding at End of Ye	erve and Medical Incenti ar	ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior	0	0	0	0	0
2. 2017	0	0	0	0	0
3. 2018	XXX	0	0	0	0
4. 2019	XXX	XXX	0	0	0
5. 2020	XXX	XXX	XXX	64,030	61,796
6. 2021	XXX	XXX	XXX	XXX	151,712

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017	0	0	0	0.0	0	0.0	0	0	0	0.0
2.	2018	0	0	0	0.0	0	0.0	0	0	0	0.0
3.	2019	0	0	0	0.0	0	0.0	0	0	0	0.0
4.	2020	76,116	61,549	3,229	5.2	64,778	85.1	247	4	65,029	85.4
5.	2021	169,264	125,701	7,552	6.0	133,253	78.7	26,011	496	159,760	94.4

UNDERWRITING AND INVESTMENT EXHIBIT

	PART 2D - A	GGREGATE RESER\	/E FOR ACCIDENT	T AND HEALTH CO	NTRACTS ONLY				
	1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other
4. U	Total	(Hospital & Medical)	Supplement	Dental Only	VISION ONly	Benefits Plan	Wedicare	iviedicald	Other
Unearned premium reserves	0								
2. Additional policy reserves (a)	0								
Reserve for future contingent benefits	0								
Reserve for rate credits or experience rating refunds (including									
\$) for investment income	1,235,861						1,235,861		
Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	
6. Totals (gross)	1,235,861	0	0	0	0	0	1,235,861	0	
7. Reinsurance ceded	0								
8. Totals (Net)(Page 3, Line 4)	1,235,861	0	0	0	0	0	1,235,861	0	
Present value of amounts not yet due on claims							,,		
Reserve for future contingent benefits	0								
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	
12. Totals (gross)			0	0	0	0	0	0	
13. Reinsurance ceded	0		0	0					
14. Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	
DETAILS OF WRITE-INS									
0501.									
0502.									
0503.									
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	1
1101.									
1102.									
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	

(a) Includes \$ _____ premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

	1	4	5			
		Claim Adjustme 1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	3 General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$ for occupancy of					
	own building)	112,709	91,605	21,114	15	225,443
2.	Salary, wages and other benefits	·		4,210,212		9, 162,341
3.	Commissions (less \$,,,,,,	, ,	,	, , ,
-	ceded plus \$assumed)	0	0	4 553 420	0	4 553 420
4.	Legal fees and expenses					
5.	Certifications and accreditation fees					0
6.	Auditing, actuarial and other consulting services					947,733
7.	Traveling expenses			39,252		41,437
8.	Marketing and advertising			4,583,950		•
9.	Postage, express and telephone			155.318		
	Printing and office supplies			17,863		,
10.				0		,
11.	Occupancy, depreciation and amortization					0
12.	Equipment	47		59,019	41 [59,472
13.	Cost or depreciation of EDP equipment and software	20,980	22,598	178, 165	123	221,866
14.	Outsourced services including EDP, claims, and					
	other services					3,781,396
15.	Boards, bureaus and association fees			8,066		8,706
16.	Insurance, except on real estate					93,643
17.	Collection and bank service charges					
18.	Group service and administration fees	·	·			92,805
19.	Reimbursements by uninsured plans					0
20.	Reimbursements from fiscal intermediaries	0	0	0	0	0
21.	Real estate expenses	444	155	63,574	44	64,217
22.	Real estate taxes	0	0	10,930	0	10,930
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes	0	0	(572,305)	0	(572,305
	23.2 State premium taxes	0	0	0	0	0
	23.3 Regulatory authority licenses and fees	1,942	263	114,454	0	116,659
	23.4 Payroll taxes	207,902	81,692	261,026	0	550,620
	23.5 Other (excluding federal income and real estate taxes)	0	0	10,869	0	10,869
24.	Investment expenses not included elsewhere	0	0	0	11,499	11,499
25.	Aggregate write-ins for expenses	96,240	877,817	646,302	446	1,620,805
26.	Total expenses incurred (Lines 1 to 25)	5 , 177 ,503	3,200,988	17,701,718	20,701 (a)26,100,910
27.	Less expenses unpaid December 31, current year .		500,564	4,180		504,744
28.	Add expenses unpaid December 31, prior year		263,115	2,447,878		2,710,993
29.	Amounts receivable relating to uninsured plans, prior year			606,445		606,445
30.	Amounts receivable relating to uninsured plans, current year			3,446,916		3,446,916
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	5,177,503	2,963,539	22,985,887	20,701	31,147,630
	DETAILS OF WRITE-INS					
2501.	Miscellaneous expenses	96,240	877,817	646,302	446	1,620,805
2502.						
2503.						
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25	96,240	877.817	646,302	446	1,620,805
· · ·	above) des management fees of \$20,319,878 t	o affiliates and \$		n-affiliates.	440	1,020,805

(a) Includes management fees of \$ 20,319,878 to affiliates and \$ to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

			1	2	
				Earned During Y	
1.	U.S. government bonds	(a)	0		0
1.1	Bonds exempt from U.S. tax				
1.2	Other bonds (unaffiliated)	(a)	247, 174	249	,024
1.3	Bonds of affiliates		0		0
2.1	Preferred stocks (unaffiliated)		0		0
2.11	Preferred stocks of affiliates	(b)	0		0
2.2	Common stocks (unaffiliated)				0
2.21	Common stocks of affiliates		0		0
3.	Mortgage loans	()	0		0
4.	Real estate	(d)	0		0
5	Contract Loans		0		0
6	Cash, cash equivalents and short-term investments	(e)	27,578	27	7,578
7	Derivative instruments	(f)	0		0
8.	Other invested assets				
9.	Aggregate write-ins for investment income		1 , 159	3	3, 187
10.	Total gross investment income		275,911		789,
11.	Investment expenses			(g)20	701
12.	Investment taxes, licenses and fees, excluding federal income taxes				0
13.	Interest expense			(h)	
14.	Depreciation on real estate and other invested assets			(i)	
5.	Aggregate write-ins for deductions from investment income				0
6.	Total deductions (Lines 11 through 15)			20),701
17.	Net investment income (Line 10 minus Line 16)			259	9,088
	DETAILS OF WRITE-INS				
901.	Securities Lending		1, 159	3	3, 187
902.	· ·				
903.					
998.	Summary of remaining write-ins for Line 9 from overflow page		0		0
999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)		1,159	3	3, 187
501.		<u> </u>	, , , , , , , , , , , , , , , , , , ,		
502.					
503.					
598.	Summary of remaining write-ins for Line 15 from overflow page				
	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)				0

(a) Includes \$	13,915	accrual of discount less \$177,255	amortization of premium and less \$0	paid for accrued interest on purchases.
(b) Includes \$	0	accrual of discount less \$0	amortization of premium and less \$0	paid for accrued dividends on purchases
(c) Includes \$	0	accrual of discount less \$0	amortization of premium and less \$	paid for accrued interest on purchases.
(d) Includes \$		for company's occupancy of its own building	s; and excludes \$ interest on encu	imbrances.
(e) Includes \$		accrual of discount less \$	amortization of premium and less \$	paid for accrued interest on purchases.
(f) Includes \$		accrual of discount less \$	amortization of premium.	
	and Separate Acco		investment taxes, licenses and fees, excluding fed-	eral income taxes, attributable to
(h) Includes \$		interest on surplus notes and \$	interest on capital notes.	
(i) Includes ¢	۸	depresiation on real actate and C	depreciation on other invested assets	

EXHIBIT OF CAPITAL GAINS (LOSSES)

		1	2	2	4	5
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	0	0	0	0	0
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)	178,863	0	178,863	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	(901,900)	0
3.	Mortgage loans		0	0	0	0
4.	Real estate		0	0		0
5.	Contract loans			0		
6.	Cash, cash equivalents and short-term investments			0		
7.	Derivative instruments			0		
8.	Other invested assets		0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	178,863	0	178,863	(901,900)	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

		Current Year Total	2 Prior Year Total	Change in Total Nonadmitted Assets
1	Bonds (Schedule D)	Nonadmitted Assets	Nonadmitted Assets	(Col. 2 - Col. 1)
				0
2.	Stocks (Schedule D):			0
	2.1 Preferred stocks 2.2 Common stocks		2 220 256	0
0			2,230,230	2,230,230
3.	Mortgage loans on real estate (Schedule B):			0
	3.1 First liens			0
	3.2 Other than first liens			0
4.	Real estate (Schedule A):			0
	4.1 Properties occupied by the company			_
	4.2 Properties held for the production of income.			
_	4.3 Properties held for sale			0
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			
6.	Contract loans			_
7.	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			0
9.	Receivables for securities			0
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)	0	2,238,256	2,238,256
13.	Title plants (for Title insurers only)			0
14.	Investment income due and accrued			0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection	59,437	6, 192	(53,245
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due \dots			0
	15.3 Accrued retrospective premiums and contracts subject to redetermination			0
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			0
	16.2 Funds held by or deposited with reinsured companies			0
	16.3 Other amounts receivable under reinsurance contracts			0
17.	Amounts receivable relating to uninsured plans			0
18.1	Current federal and foreign income tax recoverable and interest thereon			0
18.2	Net deferred tax asset		13,240	13,240
19.	Guaranty funds receivable or on deposit			0
20.	Electronic data processing equipment and software			0
21.	Furniture and equipment, including health care delivery assets			0
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0
23.	Receivable from parent, subsidiaries and affiliates			0
24.	Health care and other amounts receivable	163, 195	1,603	(161,592
25.	Aggregate write-ins for other than invested assets			
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			2,390,054
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			
28.	Total (Lines 26 and 27)	479,741	2,869,795	2,390,054
	DETAILS OF WRITE-INS			
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid Expense	257, 109	610,504	353,395
2502.				
2503.				
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	257, 109	610,504	353,395

17

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

		Total Members at End of				
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months
Health Maintenance Organizations		12,719	13,467	13,977	14, 152	160,585
Provider Service Organizations						
Preferred Provider Organizations						
4. Point of Service						
5. Indemnity Only						
Aggregate write-ins for other lines of business.	0	0	0	0	0	0
7. Total	7,646	12,719	13,467	13,977	14, 152	160,585
DETAILS OF WRITE-INS						
0601.						
0602.						
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of AMH Health, LLC (the "Company") have been prepared in conformity with the National Association of Insurance Commissioners' ("NAIC") *Annual Statement Instructions* and in accordance with accounting practices prescribed by the NAIC *Accounting Practices and Procedures Manual* ("NAIC SAP"), subject to any deviations prescribed or permitted by the Maine Bureau of Insurance ("Bureau").

A reconciliation of the Company's net income (loss) and capital and surplus between NAIC SAP and practices prescribed and permitted by the Bureau is shown below:

		SSAP#	F/S Page	F/S Line #	2021	2020
Net	Income					
(1)	AMH Health, LLC. state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ (5,823,045)	\$ (981,719)
(2)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(3)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(4)	NAIC SAP (1-2-3=4)	_XXX_	XXX	XXX	\$ (5,823,045)	\$ (981,719)
<u>Sur</u>	<u>plus</u>					
(5)	AMH Health, LLC. state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 30,741,705	\$ 14,101,828
(6)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(7)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(8)	NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$ 30,741,705	\$ 14,101,828

B. Use of Estimates in the Preparation of the Financial Statements

Preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

C. Accounting Policies

Health premiums are earned over the term of the related insurance policies. Premiums written are reported net of excess loss reinsurance ceded and experience rating refunds. Unearned premium reserves are established to cover the unexpired portion of premiums written and are computed by pro rata methods for direct business. Premiums paid by subscribers prior to the effective date are recorded on the balance sheet as premiums received in advance and are subsequently credited to income as earned during the coverage period Premium rates for certain lines of business are subject to approval by the Bureau. Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred. All other costs, including underwriting expenses, are charged to operations as incurred.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments with maturities of less than one year and more than three months at the date of acquisition and are reported at amortized cost, which approximates fair value. Non-investment grade short-term investments are stated at the lower of amortized cost or fair value.
- (2) Investment grade bonds not backed by other loans are stated at amortized cost, with amortization calculated based on the modified scientific method, using lower of yield to call or yield to maturity. Non-investment grade bonds are stated at the lower of amortized cost or fair value as determined by various third-party pricing sources.

The Company holds 18 SVO-Identified bond exchange traded funds ("ETFs") reported as bonds on Schedule D-1 in which the Company has made an irrevocable decision to report at systematic value. Systematic valuation has been consistently applied to these ETFs held at December 31, 2021 and previous periods.

- (3) The Company has no investments in common stocks of unaffiliated companies.
- (4) The Company has no investments in preferred stocks.
- (5) The Company has no mortgage loans real estate.
- (6) The Company has no loan-backed securities.
- (7) The Company owns 100% of the common stock of AMH Health Plans of Maine, Inc. ("AMH Health Plans of Maine"), a Maine domiciled stock insurance company. The Company's investment is carried at its statutory book value. The company reports net change in the equity of its subsidiary as a change in net unrealized gains and losses.
- (8) The Company has no investments in joint ventures, partnerships or limited liability companies.
- (9) The Company has no derivative instruments.
- (10) The Company recognizes losses from other-than-temporary impairments ("OTTI") of investments in accordance with Statements of Standard Accounting Practice ("SSAP") No. 26R, *Bonds*; and SSAP No. 30, *Common Stock*; and SSAP No. 32R, *Preferred Stock*.
- (11) The Company does not anticipate investment income as a factor in premium deficiency calculations.
- (12) Unpaid claims and claims adjustment expenses include management's best estimate of amounts based on historical claim development patterns and certain individual case estimates. The established liability considers health benefit provisions, business practices, economic conditions and other factors that may materially affect the cost, frequency and severity of claims. Liabilities for unpaid claims and claim adjustment expenses are based on assumptions and estimates, and while management believes such estimates are reasonable, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liabilities are continually reviewed and changes in estimates are incorporated into current period estimates.
- (13) The Company has not modified its capitalization policy from the prior period.

D. Going Concern

Not applicable.

2. Accounting Changes and Corrections of Errors

There were no accounting changes or corrections of errors during the years ended December 31, 2021 and 2020.

3. Business Combinations and Goodwill

A. Business Combinations and Goodwill

Not applicable.

B. Statutory Merger

Not applicable.

C. Assumption Reinsurance

Not applicable.

D. Impairment Loss

Not applicable.

4. Discontinued Operations

The Company had no operations that were discontinued during 2021 or 2020.

5. Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

The Company did not have investments in mortgage loans at December 31, 2021 or 2020.

B. Debt Restructuring

The Company did not have invested assets that were restructured debt at December 31, 2021 or 2020.

C. Reverse Mortgages

The Company did not have investments in reverse mortgages at December 31, 2021 or 2020.

D. Loan-Backed Securities

- (1) The Company did not have loan-backed securities at December 31, 2021 and 2020.
- (2) The Company did not recognize OTTI on its loan-backed securities during the years ended December 31, 2021 and 2020.
- (3) The Company did not hold OTTI on its loan-backed securities at December 31, 2021 and 2020.
- (4) The Company had no impaired loan-backed securities for which an OTTI had not been recognized in earnings at December 31, 2021 and 2020.
- (5) The Company had no impaired loan-backed securities at December 31, 2021 and 2020.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

- (1) The Company did not enter into repurchase agreements at December 31, 2021 or 2020.
- (2) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers based on, among other things, their creditworthiness in exchange for collateral initially equal to at least 102% of the market value of the loaned securities. The Company receives the collateral in cash or securities, and if cash is received the cash collateral is thereafter invested according to guidelines of the Company's Investment Policy.

(3) Collateral Received

a. Aggregate amount collateral received

			<u>F</u> :	<u>air Value</u>
1.	Secu	urities Lending		
	(a)	Open	\$	_
	(b)	30 days or less		_
	(c)	31 to 60 days		_
	(d)	61 to 90 days		_
	(e)	Greater than 90 days		
	(f)	Sub-total	\$	_
	(g)	Securities received		1,561,239
	(h)	Total collateral received	\$	1,561,239

- 2. Dollar repurchase agreement Not applicable.
- b. The fair value of that collateral and of the portion of that collateral that it has sold or repledged \$\\$1,561,239\$
- c. The Company receives cash collateral in an amount in excess of fair value of the securities lent. The Company reinvests the cash collateral according to guidelines of the Company's Investment Policy.
- (4) The Company does not have any securities lending transactions administered by an affiliated agent.

(5) Collateral Reinvestment

a. Aggregate amount collateral reinvested

		<u>Ar</u>	nortized Cost	<u>Fair Value</u>
1. Se	ecurities Lending			
(a) Open	\$	_	\$ _
(b) 30 days or less		_	_
(c	31 to 60 days		_	_
(d) 61 to 90 days		_	
(e	91 to 120 days		_	_
(f)	121 to 180 days		_	_
(g) 181 to 365 days		_	
(h	1 to 2 years		_	_
(i)	2 to 3 years		=	
(j)	Greater than 3 years			<u> </u>
(k) Sub-total	\$	_	\$ _
(1)	Securities received		1,561,239	1,561,239
(n	n) Total collateral reinvested	\$	1,561,239	\$ 1,561,239

- 2. Dollar repurchase agreement Not applicable.
- b. Not applicable.
- (6) Not applicable.
- (7) Not applicable.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into repurchase agreement transactions accounted for as secured borrowing at December 31, 2021 or 2020.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into reverse repurchase agreement transactions accounted for as a secured borrowing at December 31, 2021 or 2020.

H. Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into repurchase agreement transactions accounted for as a sale at December 31, 2021 or 2020.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into reverse repurchase agreement transactions accounted for as a sale at December 31, 2021 or 2020.

J. Real Estate

The Company did not have investments in real estate and did not engage in retail land sales operations during 2021 or 2020.

K. Investments in Low-Income Housing Tax Credits

The Company did not invest in properties generating low-income housing tax credits during 2021 or 2020.

L. Restricted Assets

(1) Restricted assets (including pledged)

		1	2	3	4	5	6	7
Res	stricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross Admitted and Nonadmitted Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a.	Subject to contractual obligation for which liability is not shown	\$ —	\$ —	s —	\$ —	s —	0.00 %	0.00 %
b.	Collateral held under security lending agreements	1,561,239	_	1,561,239	_	1,561,239	1.37 %	1.37 %
c.	Subject to repurchase agreements	_	_	_	_	_	0.00 %	0.00 %
d.	Subject to reverse repurchase agreements	_	_	_	_	_	0.00 %	0.00 %
e.	Subject to dollar repurchase agreements	_	_	_	_	_	0.00 %	0.00 %
f.	Subject to dollar reverse repurchase agreements	_	_	_	_	_	0.00 %	0.00 %
g.	Placed under option contracts	_	_	_	_	_	0.00 %	0.00 %
h.	Letter stock or securities restricted as to sale-excluding FHLB capital stock	_	_	_	_	_	0.00 %	0.00 %
i.	FHLB capital stock	_	_	_	_	_	0.00 %	0.00 %
j.	On deposit with states	116,263	119,484	(3,221)	_	116,263	0.10 %	0.10 %
k.	On deposit with other regulatory bodies	_	_	_	_	_	0.00 %	0.00 %
1.	Pledged as collateral to FHLB (including assets backing funding agreements)	_	_	_	_	_	0.00 %	0.00 %
m.	Pledged as collateral not captured in other categories	_	_	_	_	_	0.00 %	0.00 %
n.	Other restricted assets	_	_	_	_	_	0.00 %	0.00 %
o.	Total Restricted Assets	\$ 1,677,502	\$ 119,484	\$ 1,558,018	s –	\$ 1,677,502	1.47 %	1.47 %

⁽a) Column 1 divided by Asset Page, Column 1, Line 28

- (2) Not applicable.
- (3) Not applicable.

⁽b) Column 5 divided by Asset Page, Column 3, Line 28

(4)
Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

		1	2	3	4
	Collateral Assets	Book/ Adjusted Carrying Value (BACV)	Fair Value	% of BACV to Total Assets (Admitted and Nonadmitted*)	% of BACV to Total Admitted Assets **
a.	Cash	\$	\$ —	— %	— %
b.	Schedule D, Part 1	_	_	_	_
c.	Schedule D, Part 2 Section 1	_	_	_	
d.	Schedule D, Part 2 Section 2	_	_	_	_
e.	Schedule B	_	_	_	_
f.	Schedule A	_	_	_	_
g.	Schedule BA, Part 1	_	_	_	_
h.	Schedule DL, Part 1	1,561,239	1,561,239	1.37	1.37
i.	Other	_	_	_	_
j.	Total Collateral Assets (a+b+c+d+e+f+g+h+i)	\$ 1,561,239	\$ 1,561,239	1.37 %	1.37 %

^{*} Column 1 divided by Asset Page, Line 26 (Column 1)

M. Working Capital Finance Investments

The Company did not have any working capital finance investments at December 31, 2021 and 2020.

N. Offsetting and Netting of Assets and Liabilities

The Company did not have any offsetting or netting of assets and liabilities at December 31, 2021 and 2020.

O. 5GI Securities

The Company has no 5GI Securities as of December 31, 2021 and 2020.

P. Short Sales

The Company did not have any short sales at December 31, 2021 and 2020.

Q. Prepayment Penalty and Acceleration Fees

The Company did not have any prepayment penalty or acceleration fees at December 31, 2021 and 2020.

R. Reporting Entity's Share of Cash Pool by Asset Type

The Company did not participate in a cash pool at December 31, 2021.

^{**} Column 1 divided by Asset Page, Line 26 (Column 3)

^{*} Column 1 divided by Liability Page, Line 24 (Column 3)

6. Joint Ventures, Partnerships and Limited Liability Companies

- **A.** The Company has no investments in joint ventures, partnerships or LLCs.
- **B.** Not applicable.

7. Investment Income

- **A.** All investment income due and accrued with amounts that are over 90 days past due is non-admitted.
- **B.** At December 31, 2021 and 2020 there was no nonadmitted accrued investment income.

8. Derivative Instruments

The Company has no derivative instruments.

9. Income Taxes

A. The components of net deferred tax assets (liabilities):

(1) The components of net deferred tax asset (liabilities) are as follows:

			12/31/2021	
		(1)	(2)	(3)
		Ordinary	Capital	(Col 1+2) Total
(a)	Gross Deferred Tax Assets	\$1,419,174	\$ 22,026	\$ 1,441,200
(b)	Statutory Valuation Allowance Adjustments	1,186,388	22,026	1,208,414
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	232,786	_	232,786
(d)	Deferred Tax Assets Nonadmitted		_	
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	232,786	_	232,786
(f)	Deferred Tax Liabilities		_	_
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ 232,786	\$ —	\$ 232,786
			12/31/2020	
		(4)	(5)	(6)
		Ordinary	Capital	(Col 4+5) Total
(a)	Gross Deferred Tax Assets	\$ 258,019	\$ —	\$ 258,019
(b)	Statutory Valuation Allowance Adjustments			
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	258,019	_	258,019
(d)	Deferred Tax Assets Nonadmitted	13,240	_	13,240
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	244,779	_	244,779
(f)	Deferred Tax Liabilities		1	1
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ 244,779	\$ (1)	\$ 244,778
			Change	
		(7)	(8)	(9)
		(Col 1-4) Ordinary	(Col 2-5) Capital	(Col 7+8) Total
	Gross Deferred Tax Assets	\$1,161,155	· · · · · · · · · · · · · · · · · · ·	\$ 1,183,181
(b)	Statutory Valuation Allowance Adjustments	1,186,388	22,026	1,208,414
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	(25,233)		(25,233)
(d)	Deferred Tax Assets Nonadmitted	(13,240)		(13,240)
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	(11,993)		(11,993)
(f)	Deferred Tax Liabilities		(1)	(1)
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ (11,993)	\$ 1	\$ (11,992)

(2) The amount of admitted adjusted gross deferred tax assets under each component of SSAP No. 101, *Income Taxes* ("SSAP No. 101") are as follows:

	11 110. 101, meome 1axes (55111 110. 101) are			19/91/9991	
		(1)		(2)	(3)
					(Col 1+2) Total
Adr	nission Calculation Components SSAP No. 101	Ordin	агу	Capital	1 Otal
(a)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.	\$ 232	2,786	s —	\$ 232,786
(b)	Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	Ψ 232		—	
	Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.		_	_	_
	2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.		XXX	XXX	3,156,995
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.			_	
(d)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	\$ 232	2,786	\$	\$ 232,786
				12/31/2020	
		(4)		(5)	(6)
		Ordin	ary	Capital	(Col 4+5) Total
Adr	nission Calculation Components SSAP No. 101				
(a)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.	\$ 240	,686	\$ —	\$ 240,686
(b)	Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	4	,092	_	4,092
	 Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 	4	,092	_	4,092
	2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.		XXX	XXX	2,078,557
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.		1	_	1
(d)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	\$ 244	,779	<u>\$</u>	\$ 244,779
				Change	
		(7)		(8)	(9)
		(Col 1 Ordin		(Col 2-5) Capital	(Col 7+8) Total
Adr	nission Calculation Components SSAP No. 101			•	'
(a)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.	\$ (7	,900)	\$ —	\$ (7,900)
(b)	Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	(4	,092)	_	(4,092)
	Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.	`	,092)	_	(4,092)
	Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	`	XXX	XXX	
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.		(1)		(1)
(d)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	\$ (11	,993)	\$ —	\$ (11,993)
	(-(-) -(-))		<i>,)</i>		. (,-,-)

(3)
(a) Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.

(b) Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.

(c) 3021 2020 418.36% 387.89 %

(b) Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.

(c) 31,569,948 \$13,857,050

(4)	12/31	/2021	12/31	/2020	Cha	ınge
	(1)	(2)	(3)	(4)	(5)	(6)
	Ordinary	Capital	Ordinary	Capital	(Col 1-3) Ordinary	(Col 2-4) Capital
Impact of Tax-Planning Strategi	es					
(a) Determination of Adjusted Gross Deferred Tax Assets and Net Admitted Deferred Tax Assets, By Tax Charac As A Percentage.						
1. Adjusted Gross DTAs Amount From Note 9A1(c)	\$232,786	\$ —	\$258,019	\$ —	\$(25,233)	s —

2. Percentage of Adjusted Gross DTAs By Tax Character Attributable To The Impact Of Tax Planning Strategies

3. Net Admitted Adjusted Gross DTAs Amount From Note 9A1(e)

4. Percentage of Net
Admitted Adjusted Gross
DTAs By Tax Character
Admitted Because Of The
Impact Of Tax Planning
Strategies

 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %
 0.00 %

0.00 %

(b) Does the Company's tax-planning strategies include the use of reinsurance?

Yes No X

0.00 %

0.00 %

0.00%

B. The Company has no unrecognized deferred tax liabilities at December 31, 2021 and 2020.

0.00%

0.00 %

C. Current income taxes incurred consist of the following major components:

		(1)	(2)	(3)
		12/31/2021	12/31/2020	(Col 1-2) Change
(1) Cu	rrent Income Tax			
(a)	Federal	\$ (1,165,746)	\$ 258,736	\$ (1,424,482)
(b)	Foreign	 _	_	
(c)	Subtotal	(1,165,746)	258,736	(1,424,482)
(d)	Federal income tax expense on net capital gains	26,353	_	26,353
(e)	Utilization of capital loss carry-forwards	1,153,402	_	1,153,402
(f)	Other	_	_	_
(g)	Federal and foreign income taxes incurred	\$ 14,009	\$ 258,736	\$ (244,727)

				(1)	(2)	(3)
					(2)	(Col 1-2)
				12/31/2021	12/31/2020	Change
(2)	Def	erred T	Γax Assets:			
	(a)	Ordin	nary			
		(1)	Discounting of unpaid losses	\$ 76,912	•	·
		(2)	Unearned premium reserve	464	416	48
		(3)	Policyholder reserves	126,000	63,000	63,000
		(4)	Investments	_	_	_
		(5)	Deferred acquisition costs	_	_	_
		(6)	Policyholder dividends accrual	_	_	_
		(7)	Fixed assets	_	_	_
		(8)	Compensation and benefits accrual	_	_	_
		(9)	Pension accrual	_	_	_
		(10)	Receivables - nonadmitted	46,753	1,637	45,116
		(11)	Net operating loss carry-forward	1,153,402	_	1,153,402
		(12)	Tax credit carry-forward	_	_	_
		(13)	Other (including items <5% of total ordinary tax assets)	_	_	_
		(14)	Amortization	15,643	16,847	(1,204)
		(14) (15)	Prepaid expenses		128,206	(1,204)
		(13)	(99) Subtotal	1,419,174	258,019	1,161,155
	(b)	Statu	tory valuation allowance adjustment	1,186,388		1,186,388
	(c)		dmitted		13,240	(13,240)
	(d)		itted ordinary deferred tax assets (2a99 - 2b - 2c)	232,786	244,779	(11,993)
	(e) Capital			232,700	244,779	(11,555)
	(0)	Сарп	ui			
		(1)	Investments	22,026	_	22,026
		(2)	Net capital loss carry-forward	_	_	_
		(3)	Real estate	_	_	
		(4)	Other (including items <5% of total capital tax assets)			
			(99) Subtotal	22,026	_	22,026
	(f)	Statu	tory valuation allowance adjustment	22,026	_	22,026
	(g)		dmitted			
	(h)		itted capital deferred tax assets (2e99 - 2f - 2g)		<u> </u>	
	(i)	Adm	itted deferred tax assets (2d + 2h)	\$ 232,786	\$ 244,779	\$ (11,993)
(3)	Def	erred T	Γax Liabilities:			
	(a)	Ordin	nary			
		(1)	Investments	\$ —	\$ —	\$ —
		(2)	Fixed assets	_	_	_
		(3)	Deferred and uncollected premium	_	_	_
		(4)	Policyholder reserves	_	_	_
		(5)	Other (including items <5% of total ordinary tax liabilities)			
			(99) Subtotal	_	_	_
	(b)	Capit	al			
		(1)	Investments	_	1	(1)
		(2)	Real estate	_	_	_
		(3)	Other (including items <5% of total capital tax liabilities)	_	_	_
			(99) Subtotal		1	(1)
	(c)	Defe	rred tax liabilities (3a99 + 3b99)		1	(1)
(4)			ed tax assets/liabilities (2i - 3c)	\$ 232,786	\$ 244,778	

D. The Company's income tax expense and change in deferred income taxes differs from the amount obtained by applying the federal statutory income tax rate of 21% for the year ended December 31 as follows:

	 2021	2020
Tax expense computed using federal statutory rate	\$ (1,219,898) \$	(151,827)
ACA health insurer fee	_	282,863
Change in nonadmitted assets	29,097	(129,843)
Tax exempt income and dividend received deduction net of proration	(280)	(287)
Tax exempt income received net of proration	20,450	_
Intercompany dividends	1,208,414	_
Other, net	1,458	_
Total	\$ 39,241 \$	906
Federal income taxes incurred	\$ 14,009 \$	258,736
Change in net deferred income taxes	 25,232	(257,830)
Total statutory income taxes	\$ 39,241 \$	906

E. Operating loss carryforwards:

(1) At December 31, 2021, the Company had the following unused net operating loss or tax credit carryforwards available to offset future taxable income. The losses or credits will begin to expire as noted.

 Unused NOL	Will Begin to	Unused Tax Credit	Will begin to
Carryforwards	Expire	Carryforwards	Expire
\$ 5,492,390	2041	\$ —	

(2) The following are income taxes incurred in the current and prior year(s) that will be available for recoupment in the event of future net losses:

	Ordinary	Capital	Total
2021 \$	— \$	— \$	_
2020	232,786	_	232,786
2019	N/A	_	_

- (3) The Company has no protective tax deposits reported as admitted assets under Section 6603 of the Internal Revenue Service Code as of December 31, 2021 and 2020.
- **F.** The Company's Federal Income Tax return is a separate filing. No owner has the required 80% to include them in a consolidated return. Thus, no tax sharing agreement is in place for federal income taxes. As of December 31, 2021, the statute of limitations of the 2021, 2020 and 2019 tax year remains open.

G. Not applicable.

H. Repatriation Transition Tax (RTT)

Not applicable.

I. Alternative Minimum Tax (AMT) Credit

Not applicable.

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. Nature of the Relationship

The Company is a Maine domiciled joint venture limited liability company health maintenance organization ("HMO") which is owned 50% by Anthem Partnership Holding Company, LLC ("APHC"), which is a wholly owned direct subsidiary of Anthem, Inc. ("Anthem"), a publicly traded company, and 50% by MaineHealth, a not-for-profit corporation with hospitals, providers, and healthcare organizations primarily located in Maine.

As of December 31, 2021, APHC owns 1 common membership unit and 18,000 preferred membership units and MainHealth owns one common membership unit.

B. Significant Transactions for Each Period

The following significant transactions took place between the Company and its affiliates:

The Company received a capital contribution of \$6,500,000 from Anthem Partnership Holding Company, LLC ("APHC") on December 22, 2021. In return, APHC received 6,500 preferred membership units.

The Company received a capital contribution of \$6,500,000 from MaineHealth on December 22, 2021. In return, MaineHealth received 6,500 preferred membership units.

The Company paid an additional capital contribution of \$2,000,000 to AMH Health Plans of Maine, Inc. on September 29, 2021.

The Company received a capital contribution of \$4,000,000 from Anthem Partnership Holding Company, LLC ("APHC") on June 28, 2021. In return, APHC received 4,000 preferred membership units.

The Company received a capital contribution of \$4,000,000 from MaineHealth on June 28, 2021. In return, MaineHealth received 4,000 preferred membership units.

The Company paid an additional capital contribution of \$600,000 to AMH Health Plans of Maine, Inc. on March 31, 2021.

The Company paid an additional capital contribution of \$400,000 to AMH Health Plans of Maine on December 31, 2020.

The Company received a capital contribution of \$7,500,000 from APHC on December 30, 2020. In return, AHPC received 7,500 preferred membership units.

The Company received a capital contribution of \$4,000,000 from APHC on June 30, 2020. In return, AHPC received 4,000 preferred membership units.

The Company paid an initial capital contribution of \$2,000,000 to AMH Health Plans of Maine on March 26, 2020.

For changes to the intercompany management and service arrangements see Note 10E. The amounts of transactions under such agreements are presented in Schedule Y, Part 2.

C. Transactions with Related Parties who are not Reported on Schedule Y

The Company has no transactions with related parties who are not reported on Schedule Y.

D. Amounts Due to or from Related Parties

At December 31, 2021 and 2020, the Company reported no amounts due from affiliates. At December 31, 2021 and 2020, the Company reported \$53,094,668 and \$24,869,703 due to affiliates, respectively. The receivable and payable balances represent intercompany transactions that will be settled in accordance with the settlement terms of the intercompany agreement.

E. Management and Service Contracts and Cost Sharing Arrangements

During 2020, the Company amended the administrative services agreement with APHC and MaineHealth to confirm reporting and oversight responsibilities relating to utilization management for behavioral health services.

In addition, the Company has entered into a joinder affiliated services agreement as part of the Master Services Agreement between Anthem affiliates and Beacon Health Strategies LLC and Beacon Health Options, Inc., effective January 1, 2021.

On February 15, 2019, the Company entered into an administrative services agreement with APHC and MaineHealth. Pursuant to these agreements, various administrative, management and support services are provided to or provided by the Company. Costs include expenses such as salaries, employees benefits, information technology, pharmacy benefits administration, communications, advertising, consulting services, rent, utilities, billing, accounting, underwriting, and product development which support the Company's operations.

F. Guarantees or Contingencies for Related Parties

The Company did not enter into guarantees or undertakings for the benefit of an affiliate which would result in a material contingent exposure of the Company's or any affiliated insurer's assets or liabilities.

G. Nature of Control Relationships that Could Affect Operations or Financial Position

The Company is owned 50% by APHC and 50% by MaineHealth.

H. Amount Deducted for Investment in Upstream Company

The Company does not own shares of upstream intermediate entities or Anthem.

I. Detail of Investments in Affiliates Greater than 10% of Admitted Assets

The Company does not have investments in affiliates greater than 10% of admitted assets.

J. Write-down for Impairments of Investments in Subsidiaries, Controlled or Affiliated ("SCA") Companies

Not applicable.

K. Investment in a Foreign Insurance Subsidiary

The Company does not have investments in foreign insurance subsidiaries.

L. Investment in Downstream Non-insurance Holding Companies

The Company does not have investments in downstream non-insurance holding companies.

M. All SCA Investments

The Company has no SCA Investments.

N. Investment in Insurance SCAs

The Company does not have investments in Insurance SCAs.

O. SCA or SSAP 48 Entity Loss Tracking

The Company does not have losses on investments in Insurance SCAs and/or joint ventures, partnerships or LLCs.

11. Debt

A. Capital Notes and Other Debt

The Company had no capital notes or other debt outstanding at December 31, 2021 and 2020.

B. FHLB (Federal Home Loan Bank) Agreements

The Company had no FHLB agreements outstanding at December 31, 2021 and 2020.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

Not applicable - See Note 12G.

- **B.** Not applicable See Note 12G.
- C. Not applicable See Note 12G.
- **D.** Not applicable See Note 12G.

E. Defined Contribution Plans

Not applicable - See Note 12G.

F. Multiemployer Plans

The Company does not participate in a multiemployer plan.

G. Consolidated/Holding Company Plans

The Company participates in a nonqualified deferred compensation plan sponsored by Anthem which covers certain employees once the participant reaches the maximum contribution amount for the Anthem 401(k) Plan (the "401(k) Plan"). The deferred amounts are payable according to the terms and subject to the conditions of the deferred compensation plan. Anthem allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees subject to the deferred compensation plan. The Company has no legal obligation for benefits under this plan.

The Company participates in the Anthem 401(k) Plan, sponsored by ATH Holding Company, LLC ("ATH Holding") and covering substantially all employees. Voluntary employee contributions are matched by ATH Holding subject to certain limitations. ATH Holding allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a stock incentive compensation plan, sponsored by Anthem, providing incentive awards to non-employee directors and employees, consisting of Anthem stock options, restricted stock, restricted stock units, stock appreciation rights, performance shares, and performance units. Anthem allocates a share of the total share-based compensation expense of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

During 2021 and 2020, the Company was allocated the following costs or (credits) for these retirement benefits:

	 2021	2020
Defined benefit pension plan	\$ 3,201 \$	1,224
Deferred compensation plan	242,237	85,356
Stock incentive compensation plan	121,380	50,754

H. Post Employment Benefits and Compensated Absences

Not applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not applicable.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

A. Outstanding Shares

The Company has no common stock outstanding.

B. Preferred Stock

The Company has no preferred stock outstanding.

C. Dividend Restrictions

Under Maine law, the Company is limited in the amount of dividends that can be declared without regulatory approval. The Superintendent of Insurance must approve any dividend that, together with all dividends declared during the preceding twelve months, exceeds the greater of the net gain from operations for the twelve-month period ending December 31 of the preceding year or 10% of the Company's surplus to policyholders as of December 31 of the preceding year as long as unassigned surplus is positive. Also, any dividend paid from other than unassigned funds will need the approval of the Superintendent of Insurance.

D. Dividends Paid

See Footnote 10B.

E. Maximum Ordinary Dividend During 2022

Within the limitations of (C) above, the Company may not pay dividends during 2022 without prior approval.

F. Unassigned Surplus Restrictions

Unassigned surplus funds are not restricted at December 31, 2021.

G. Mutual Surplus Advances

Not applicable.

H. Company Stock Held for Special Purpose

There are no shares of stock held for special purposes at December 31, 2021.

I. Changes in Special Surplus Funds

There was no change in balances of special surplus funds from the prior year. The Company did not exist in 2018.

J. Changes in Unassigned Funds

The portion of unassigned funds represented by cumulative unrealized investment gains and losses was (\$1,063,644) at December 31, 2021.

K. Surplus Notes

The Company has not issued any surplus notes or debentures or similar obligations.

L. Restatement due to Prior Quasi-reorganizations

The Company had no restatements due to prior quasi-reorganizations.

M. Quasi-reorganizations over Prior 10 Years

The Company has not been involved in a quasi-reorganization during the past 10 years.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

The Company had no contingent commitments at December 31, 2021 or 2020.

B. Assessments

- (1) The Company is subject to guaranty fund and other assessments by the state in which it writes business. Guaranty fund assessments are accrued at the time of insolvencies. Other assessments are accrued either at the time of the assessment or at the time the losses are incurred.
- (2) Not applicable.
- (3) Not applicable.

C. Gain Contingencies

The Company has no gain contingencies at December 31, 2021 or 2020.

D. Claims-Related Extra Contractual Obligation and the Bad Faith Losses Stemming From Lawsuits

Not applicable.

E. Joint and Several Liabilities

Not applicable.

F. All Other Contingencies

Medicare Risk Adjustment Litigation

In March 2020, the U.S. Department of Justice ("DOJ") filed a civil lawsuit against Anthem, Inc. in the U.S. District Court for the Southern District of New York in a case captioned United States v. Anthem, Inc. The DOJ's suit alleges, among other things, that Anthem falsely certified the accuracy of the diagnosis data they submitted to the Centers for Medicare and Medicaid Services ("CMS") for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, Anthem caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled Anthem to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its allegations. In September 2020, Anthem filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. The motions are fully briefed and no decision has been rendered. Anthem intends to continue to vigorously defend this suit, which they believe is without merit; however, the ultimate outcome cannot be presently determined.

From time to time, the Company is party to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. The Company, like HMOs and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, PPO, and other plans. The Company is, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on the Company. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.

In addition to the lawsuits described above, the Company is also involved in other pending and threatened litigation of the character incidental to their business, and is from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on the Company's business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on the Company's financial position or results of operations.

The Company has no other known material contingencies.

Provisions for uncollectible amounts

At December 31, 2021 and 2020, the Company reported admitted assets of \$7,968,768 and \$1,718,789, respectively, in premium receivables and receivables due from uninsured plans. Based upon the Company's experience, any uncollectible receivables are not expected to exceed \$59,437 that was nonadmitted at December 31, 2021; therefore, no additional provision for uncollectible amounts has been recorded. The potential for any additional loss is not believed to be material to the Company's financial condition.

15. Leases

A. Lessee Operating Lease

The Company has no lessee leasing arrangements.

B. Lessor Leases

- (1) The Company has not entered into any operating leases.
- (2) The Company has not entered into any leveraged leases.

16. Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company has no significant financial instruments with off-balance sheet risk.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of investment securities. All investment securities are managed by professional investment managers within policies authorized by the board of directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. As of December 31, 2021, there were no significant concentrations.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not applicable at December 31, 2021 and 2020.

B. Transfer and Servicing of Financial Assets

(1) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers. At December 31, 2021 the fair value of securities loaned was \$1,502,802 and the carrying value of securities loaned was \$1,495,686.

C. Wash Sales

- (1) In the course of the Company's asset management, securities may be sold and reacquired within 30 days of the sale date to enhance the yield on the investments.
- (2) At December 31, 2021 and 2020, there were no wash sales involving securities with an NAIC designation of 3 or below or unrated.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. Administrative Services Only ("ASO") Plans

Not applicable at December 31, 2021.

B. Administrative Services Contract ("ASC") Plans

Not applicable at December 31, 2021.

C. Medicare or Other Similarly Structured Cost-Based Reimbursement Contract

Not applicable at December 31, 2021 and 2020.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

No premiums were written by managing general agents or third party administrators during the years ended December 31, 2021 and 2020.

20. Fair Value Measurements

Α.

There are no assets or liabilities measured at fair value as of December 31, 2021 and 2020.

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

There are no investments in Level 3 as of December 31, 2021 and 2020.

(3) The Company's policy is to recognize transfers between Levels, if any, as of the beginning of the reporting period.

Fair values of bonds are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level 1 or Level 2 inputs, for the determination of fair value to facilitate fair value measurements and disclosures. Level 2 securities primarily include United States government securities, corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. The Company has controls in place to review the pricing services' qualifications and procedures used to determine fair values. In addition, the Company periodically reviews the pricing services' pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.

Certain bonds, primarily corporate debt securities, are designated Level 3. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

There have been no significant changes in the valuation techniques during the current period.

There are no assets or liabilities measured at fair value.

B. Fair Value Measurements Under Other Accounting Pronouncements

Not applicable at December 31, 2021 and 2020.

C. Financial Instruments

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(1	Level 3)	Net Asset Value (NAV)	Practic (Carry Valu	able ing
Bonds	\$ 26,993,471	\$ 27,016,024	\$ 26,872,828	\$ 120,643	\$	_ 5	S —	\$	_
Securities lending collateral asset	1,561,239	1,561,239	_	1,561,239		_	_		_

D. Not Practicable to Estimate Fair Value

There are no financial instruments that were not practicable to estimate fair value.

E. Investments Measured at Net Asset Value

The Company has no investments measured at net asset value.

21. Other Items

A. Unusual or Infrequent Items

The spread of the COVID-19 virus caused significant financial market volatility, economic uncertainty, and interruptions to normal business activities. The ultimate impact to the Company is unknown, but management expects continued interruptions to day-to-day business activities, impacts to claim and premium activity, investment values, as well as possible impacts to liquidity.

B. Troubled Debt Restructuring: Debtors

Not applicable at December 31, 2021 and 2020.

C. Other Disclosures

Assets in the amount of \$116,263 and \$119,484 at December 31, 2021 and 2020, respectively, were on deposit with government authorities or trustees as required by law.

D. Business Interruption Insurance Recoveries

The Company has reported no recoveries for business interruption for the years ended December 31, 2021 and 2020.

E. State Transferable and Non-Transferable Tax Credits

The Company did not have state transferable or non-transferable tax credits at December 31, 2021 and 2020.

F. Subprime Mortgage-Related Risk Exposure

- (1) The Company's investment strategy of providing safety and preservation of capital, sufficient liquidity to meet cash flow requirements and the attainment of a competitive after-tax investment return is supported by a well diversified portfolio consisting of many different types of investments. The portion of the Company's investment portfolio with subprime mortgage-related risk exposure is relatively small in comparison to the overall investment portfolio, and consists mainly of investment grade securities with no exposure to collateralized debt obligations. All mortgage related investments are monitored closely as part of the quarterly investment review performed by the Anthem Investment Impairment Review Committee.
- (2) The Company did not carry investments in subprime mortgage loans in its portfolio at December 31, 2021 or 2020.
- (3) The Company did not have subprime mortgage-related risk exposure at December 31, 2021 or 2020.
- (4) The Company did not underwrite Mortgage Guaranty or Financial Guaranty insurance coverage at December 31, 2021 or 2020.

G. Retained Assets

The Company does not have retained assets at December 31, 2021 and 2020.

H. Insurance-Linked Securities Contracts

Not applicable.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

Not applicable.

22. Events Subsequent

Subsequent events have been considered through February 25, 2022 for the statutory statement issued on February 28, 2022. There were no events occurring subsequent to December 31, 2021 requiring recognition or disclosure.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

(1) Are any of the reinsurers that are listed in Schedule S as non-affiliated owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes () No (X)

If yes, give full details.

(2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled, directly or indirectly, by an insured, a

beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?
Yes () No (X)
If yes, give full details.
Section 2 - Ceded Reinsurance Report - Part A
(1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?
Yes () No (X)
If yes, give full details.
(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?
Yes () No (X)
If yes, give full details.
Section 3 - Ceded Reinsurance Report - Part B
(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate.
\$0
(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?
Yes $()$ No (X)
If yes, give full details.

B. Uncollectible Reinsurance

The Company has no uncollectible reinsurance at December 31, 2021 and 2020.

C. Commutation of Ceded Reinsurance

The Company has not commuted ceded reinsurance during 2021 and 2020.

D. Certified Reinsurer Rating Downgraded or Status Subject Revocation

The Company has no downgraded certified reinsurer ratings or status subject to revocations during 2021 and 2020.

		revocations during 2021 and 2020.
	Ε.	Reinsurance Credit
		(1) Not applicable.
		(2) Not applicable.
		(3) Not applicable.
		(4) Not applicable.
		(5) Not applicable.
		(6) Not applicable.
24.	Re	trospectively Rated Contracts & Contracts Subject to Redetermination
	A.	The Company sells accident and health policies for which the premiums vary based on loss experience. The Company estimates retrospective premium adjustments through the review of each retrospectively rated account, comparing the claim development with that anticipated in the policy contracts.
	В.	The Company records accrued retrospective premium as an adjustment to earned premium.
	C.	All of the Company's net premiums written are subject to a retrospective rating feature.
	D.	Not applicable.
	Ε.	Risk-Sharing Provisions of the ACA
		(1) Did the reporting entity write accident and health insurance premium that is subject to the Affordable Care Act risk-sharing provisions (YES/NO)? No
		(2) Impact of Risk-Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities and Revenue for the Current Year
		Not applicable.
		(3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance.
		Not applicable.
		(4) Roll-forward of Risk Corridors Asset and Liability Balances by Program Benefit Year.
		Not applicable.
		(5) ACA Risk Corridors Receivable as of Reporting Date.

Not applicable.

25. Change in Incurred Claims and Claim Adjustment Expenses

- **A.** The estimated cost of claims and claim adjustment expense attributable to insured events of prior years decreased by \$1,442,451 during 2021. This is approximately 11.0% of unpaid claims and claim adjustment expenses of \$13,055,502 as of December 31, 2020. The redundancy reflects the decreases in estimated claims and claims adjustment expenses as a result of claims payment during the year, and as additional information is received regarding claims incurred prior to 2021. Recent claim development trends are also taken into account in evaluating the overall adequacy of unpaid claims and unpaid claim adjustment expense.
- **B.** There were no significant changes in methodologies and assumptions used in calculating the liability for unpaid losses and loss adjustment expenses. The impact from COVID-19 on healthcare utilization and medical claims submission patterns has increased estimation uncertainty on our incurred but not reported liability at December 31, 2021. Slowdowns in claims submission patterns and increases in utilization levels for COVID-19 testing and treatment during the fourth quarter of 2021 are the primary factors that lead to the increased estimation uncertainty.

26. Intercompany Pooling Arrangements

Not applicable at December 31, 2021 and 2020.

27. Structured Settlements

Not applicable at December 31, 2021 and 2020.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2021	\$ 2,125,937	\$ 5,740,967	\$ 3,585,546	\$ —	\$ —
9/30/2021	1,859,300	5,320,603	5,227,697	_	
6/30/2021	1,989,514	3,754,397	3,682,823	71,574	
3/31/2021	1,955,064	4,921,486	4,878,634	42,851	_
12/31/2020	\$ 1,209,016	\$ 3,264,527	\$ 3,260,277	\$ 4,250	\$ —
9/30/2020	631,740	2,105,778	2,082,716	23,062	_
6/30/2020	744,053	1,957,115	1,947,481	9,635	_
3/31/2020	449,890	1,002,420	1,002,420	_	_
12/31/2019	_	_	_	_	_
9/30/2019	_	_	_	_	_
6/30/2019	_	_	_	_	_
3/31/2019	_	_		_	_

B. Risk Sharing Receivables

Not applicable at December 31, 2021 and 2020.

29. Participating Policies

Not applicable at December 31, 2021 and 2020.

30. Premium Deficiency Reserves

The Company had no liabilities related to premium deficiency reserves as of December 31, 2021 and 2020.

31. Anticipated Salvage and Subrogation

The Company took into account estimated anticipated subrogation and other recoveries in its determination of the liability for unpaid claims and reduced the liability by \$111,000 and \$50,000 at December 31, 2021 and 2020, respectively.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer?		[X] N	No []
	If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.				
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent, or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations?	[X] N	0 []	N/A []
1.3	State Regulating?		Main	ıe	
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?	Yes	[X] N	No []
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group.	00	01156	6039	
2.1	Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?	Yes	[] N	No [X]
2.2	If yes, date of change:				
3.1	State as of what date the latest financial examination of the reporting entity was made or is being made.				
3.2	State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released.				
3.3	State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).				
3.4	By what department or departments?				
3.5	Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments?	[] N	0 []	N/A [X]
3.6	Have all of the recommendations within the latest financial examination report been complied with?	[] N	0 []	N/A [X]
4.1	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of: 4.11 sales of new business?	Yes			No [X]
4.2	4.12 renewals? During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct		l] N	No [X]
	premiums) of: 4.21 sales of new business?		-	-	lo [X]
5.1	Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?		-	-	
5.1	If yes, complete and file the merger history data file with the NAIC.	165	l] IN	10 [X]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.				
	1 Name of Entity NAIC Company Code State of Domicile				
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended crevoked by any governmental entity during the reporting period?		[] N	No [X]
6.2	If yes, give full information:				
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?		[] N	lo [X]
7.2	If yes, 7.21 State the percentage of foreign control;				(
	7.21 State the percentage of ideign control,)
	1 2	7			

GENERAL INTERROGATORIES

3	Is the company affiliated with one or more banks, thrifts or securities fi	rms?				Yes [1	No I	χ 1
4	If response to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commissi	n (city and state of the main office) of any affilian Office of the Comptroller of the Currency (OCC	es regulate	d by a fe ral Depo	deral	100 [,	NO [ν 1
	1	2	3	4	5	_	٦		
	Affiliate Name	Location (City, State)	FRB	OCC	FDI	C SEC	_		
.5	Is the reporting entity a depository institution holding company with sig Federal Reserve System or a subsidiary of the reporting entity?	•				Yes []	No [Х]
6	If response to 8.5 is no, is the reporting entity a company or subsidiary Federal Reserve Board's capital rule?	of a company that has otherwise been made s	ubject to th	e 	Yes [] No [Χ] N/A	[
١.	What is the name and address of the independent certified public according to the Ernst & Young LLP, 111 Monument Circle, Suite 4000, Indianapolis, In	ountant or accounting firm retained to conduct t	he annual a	udit?					
.1	Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Report law or regulation?	dit services provided by the certified independe ing Model Regulation (Model Audit Rule), or su	ent public ac	countan imilar sta	t ate	Yes []	No [Χ]
.2	If the response to 10.1 is yes, provide information related to this exem								
.3	Has the insurer been granted any exemptions related to the other requ	irements of the Annual Financial Reporting Mo	del Regulat	ion as		V [,	Ni. T	V 1
.4	allowed for in Section 18A of the Model Regulation, or substantially sir If the response to 10.3 is yes, provide information related to this exem	ption:					J	NO [X]
.5	Has the reporting entity established an Audit Committee in compliance] N/A	[
.6	If the response to 10.5 is no or n/a, please explain								
1.	What is the name, address and affiliation (officer/employee of the reportirm) of the individual providing the statement of actuarial opinion/certificence H. Smith, ASA, MAAA, Director & Actuary III, 800 E. Mill Creek	fication?	h an actuar	ial consu	ılting				
.1	Does the reporting entity own any securities of a real estate holding co						1	No [Х
		estate holding company					·	•	
		rcels involved							
.2	12.13 Total book/adj	justed carrying value				\$			
_									
3.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTIT								
.1	What changes have been made during the year in the United States n								
.2	Does this statement contain all business transacted for the reporting e Have there been any changes made to any of the trust indentures duri	entity through its United States Branch on risks	wherever lo	cated?		Yes []	No []
.4	If answer to (13.3) is yes, has the domiciliary or entry state approved the						_	_	1
	Are the senior officers (principal executive officer, principal financial of	ficer, principal accounting officer or controller, of	r persons r	erformin	a			-	١.
	similar functions) of the reporting entity subject to a code of ethics, whi a. Honest and ethical conduct, including the ethical handling of actual relationships;					Yes []	X]	No [
	b. Full, fair, accurate, timely and understandable disclosure in the period		entity;						
	c. Compliance with applicable governmental laws, rules and regulationd. The prompt internal reporting of violations to an appropriate person								
	e. Accountability for adherence to the code.	or porcorre recruired in the code, and							
11	If the response to 14.1 is No, please explain:								
.2	Has the code of ethics for senior managers been amended?					Yes [1	No [χ
	If the response to 14.2 is yes, provide information related to amendme	ent(s).				_			
.3	Have any provisions of the code of ethics been waived for any of the s						1	No [χ.
	If the response to 14.3 is yes, provide the nature of any waiver(s).	r				100 [1	[^ .

GENERAL INTERROGATORIES

2	If the response to 15.1 is yes, indicate the American Bankers Asse	ociation (ABA) Pouting Number and the name of the issuing or confirming	Yes [] No [
	bank of the Letter of Credit and describe the circumstances in whi		
	1 2 American Bankers Association (ABA) Routing	3	4
	Number Issuing or Confirming Bank Name	Circumstances That Can Trigger the Letter of Credit	Amount
,		AARD OF DIRECTORS	
	Is the purchase or sale of all investments of the reporting entity pa	DARD OF DIRECTORS assed upon either by the board of directors or a subordinate committee	Yes [X] No [
	Does the reporting entity keep a complete permanent record of the	e proceedings of its board of directors and all subordinate committees	Yes [X] No [
	Has the reporting entity an established procedure for disclosure to	o its board of directors or trustees of any material interest or affiliation on the yees that is in conflict with the official duties of such person?	Yes [X] No [
		FINANCIAL	
	Has this statement been prepared using a basis of accounting oth Accounting Principles)?	ner than Statutory Accounting Principles (e.g., Generally Accepted	Yes [] No [
	Total amount loaned during the year (inclusive of Separate Accou	ints, exclusive of policy loans): 20.11 To directors or other officers	\$
		20.12 To stockholders not officers 20.13 Trustees, supreme or grand (Fraternal Only)	.\$.\$
	Total amount of loans outstanding at the end of year (inclusive of	Separate Accounts, exclusive of	
	policy loans):	20.21 To directors or other officers	•
		20.22 To stockholders not officers	
,	Were any assets reported in this statement subject to a contractual obligation being reported in the statement?	al obligation to transfer to another party without the liability for such	
	If yes, state the amount thereof at December 31 of the current year	ar: 21.21 Rented from others	.\$
		21.22 Borrowed from others	
		21.23 Leased from others	
		21.24 Other	.\$
9	guaranty association assessments?	bed in the Annual Statement Instructions other than guaranty fund or	
	If answer is yes:	22.21 Amount paid as losses or risk adjustment	
		22.22 Amount paid as expenses	
	Deep the reporting entity report any amounts due from percent out	22.23 Other amounts paidosidiaries or affiliates on Page 2 of this statement?	
	If west indicate any amounts receivable from parent included in the	e Page 2 amount:	tes [] NO [
	Does the insurer utilize third parties to pay agent commissions in v	which the amounts advanced by the third parties are not settled in full within	
	If the response to 24.1 is yes, identify the third-party that pays the	agents and whether they are a related party.	
		Is the Third-Party Agent a Related Party	
	Name of Third-Party	(Yes/No)	
		INVESTMENT	

GENERAL INTERROGATORIES

25.02	If no, give full and complete information relating thereto					
25.03	whether collateral is carried on or off-balance sheet. (an altern	orogram including value for collateral and amount of loaned securities, and lative is to reference Note 17 where this information is also provided)				
25.04	For the reporting entity's securities lending program, report am Instructions.	nount of collateral for conforming programs as outlined in the Risk-Based Capital	\$		1,5	561,239
25.05	For the reporting entity's securities lending program, report are	nount of collateral for other programs.	.\$			
25.06	Does your securities lending program require 102% (domestic outset of the contract?	securities) and 105% (foreign securities) from the counterparty at the	X] No	[] N//	A []
25.07	Does the reporting entity non-admit when the collateral received	ed from the counterparty falls below 100%? Yes []	X] No]] N//	A []
25.08		nding agent utilize the Master Securities lending Agreement (MSLA) to	X] No	[] N/A	A []
25.09	For the reporting entity's securities lending program state the	amount of the following as of December 31 of the current year:				
	25.092 Total book adjusted/carrying value of	l assets reported on Schedule DL, Parts 1 and 2	\$		1,5	561,239
26.1	control of the reporting entity, or has the reporting entity sold of	entity owned at December 31 of the current year not exclusively under the or transferred any assets subject to a put option contract that is currently in 5.03).	Yes [[X]	No [[]
26.2	If yes, state the amount thereof at December 31 of the current	year: 26.21 Subject to repurchase agreements	\$		1	116,263
26.3	For category (26.26) provide the following:	2		3		\neg
26.3	1 Nature of Restriction	2 Description		3 mour		
26.3	1 Nature of Restriction	Description		mour		
27.1	Nature of Restriction Does the reporting entity have any hedging transactions reporting services, has a comprehensive description of the hedging program.	Description	Yes [mour	No [[X]
27.1 27.2	Nature of Restriction Does the reporting entity have any hedging transactions report	ted on Schedule DB?	Yes [mour	No [[X]
27.1 27.2 LINES 2	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions repor If yes, has a comprehensive description of the hedging progra If no, attach a description with this statement. 7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTI	ted on Schedule DB?	Yes [No [[X] A []
27.1 27.2 LINES 2	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions repor If yes, has a comprehensive description of the hedging progra If no, attach a description with this statement. 7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTI Does the reporting entity utilize derivatives to hedge variable a If the response to 27.3 is YES, does the reporting entity utilize	ted on Schedule DB?	Yes [] No Yes [Yes [Yes [[]	No [] N// No [No [No [[X] A [] [X]
27.1 27.2 LINES 2 27.3 27.4	Nature of Restriction If yes, has a comprehensive description of the hedging progra If no, attach a description with this statement. 7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTI Does the reporting entity utilize derivatives to hedge variable at If the response to 27.3 is YES, does the reporting entity utilize By responding YES to 27.41 regarding utilizing the special accollowing: The reporting entity has obtained explicit approval fro Hedging strategy subject to the special accounting properties and provides the impact of the hedging strate reserves and provides the impact of the hedging strate Financial Officer Certification has been obtained which	ted on Schedule DB?	Yes [Yes [Yes [Yes [Yes [[] []]]]	No [] N// No [No [No [[X] [X] [X]
27.1 27.2 LINES 2 27.3 27.4	Nature of Restriction If yes, has a comprehensive description of the hedging progral for, attach a description with this statement. 7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTI Does the reporting entity utilize derivatives to hedge variable at lift the response to 27.3 is YES, does the reporting entity utilize By responding YES to 27.41 regarding utilizing the special acc following: The reporting entity has obtained explicit approval from the Hedging strategy subject to the special accounting properties and provides the impact of the hedging strategy subject to the special accounting the provides the impact of the hedging strategy within VM-21 and that the Clearly District its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 3	ted on Schedule DB?	Yes [] No Yes [Yes [Yes [Yes [Yes [No [] N/# No [No [No [No [[X] [X] [X] [X]
27.1 27.2 LINES 2 27.3 27.4	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions report of the properties of the hedging program of the notation of the hedging program of the properties of the hedging of the hedging properties of the hedging provides the provides of the hedging provides the provides of the hedging provides of the hedging provides the provides of the hedging provides of the hedging provides of the provides of	ted on Schedule DB?	Yes [] No Yes [Yes [Yes [Yes [Yes [No [No [[X] [X] [X] [X]
27.1 27.2 LINES 2 27.3 27.4 27.5	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions report of the properties of the hedging program of the notation of the hedging entity utilized erivatives to hedge variable of the response to 27.3 is YES, does the reporting entity utilized by responding YES to 27.41 regarding utilizing the special accounting of the hedging strategy subject to the special accounting properties. By responding YES to 27.41 regarding utilizing the special accounting properties of the hedging strategy subject to the special accounting properties. Actuarial certification has been obtained which indicates reserves and provides the impact of the hedging strategy within VM-21 and that the Clearly Distriction has been obtained which hedging Strategy within VM-21 and that the Clearly Distriction of the current of the theory of the properties of the notation of the current of the special of the current of the properties of the special of the current of the properties of the prope	ted on Schedule DB? m been made available to the domiciliary state?	Yes [] No Yes [Yes [Yes [Yes [Yes [moui [] []]]]]]]]]]]]]]]]	No [[X] [X] [X] [] []
27.1 27.2 LINES 2 27.3 27.4 27.5	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions report of the properties of the hedging program of the notation of the hedging program of the reporting entity utilize derivatives to hedge variable of the response to 27.3 is YES, does the reporting entity utilize of the special accounting program of the reporting entity as obtained explicit approval from the deging strategy subject to the special accounting program of the entity of the hedging strategy subject to the special accounting program of the entity of the hedging strategy subject to the special accounting program of the hedging strategy within vM-21 and that the Clearly Distriction has been obtained which Hedging Strategy within vM-21 and that the Clearly Distriction of the current of the the program of the current of the program	ted on Schedule DB? m been made available to the domiciliary state?	Yes [] No Yes [moui [] []]]]]]]]]]]]]]]]	No [[X] [X] [X] [] []
27.1 27.2 LINES 2 27.3 27.4 27.5	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions report of the properties of the hedging program of the notation of the hedging program of the reporting entity utilize derivatives to hedge variable of the response to 27.3 is YES, does the reporting entity utilize of the special accounting program of the reporting entity as obtained explicit approval from the deging strategy subject to the special accounting program of the entity of the hedging strategy subject to the special accounting program of the entity of the hedging strategy subject to the special accounting program of the hedging strategy within vM-21 and that the Clearly Distriction has been obtained which Hedging Strategy within vM-21 and that the Clearly Distriction of the current of the the program of the current of the program	ted on Schedule DB? In been made available to the domiciliary state? In the sensitivity of the sensitivity	Yes [] No Yes [[] [] [] [] [] [] [] [] [] []	No [[X] [X] [X] [X]

GENERAL INTERROGATORIES

	1 Name(s)		2 Location(s)		3 Complete Explanation(s)			
	nanges, including name changlete information relating the	nanges, in the custodian(s) i thereto:	dentified in 29.01	during the current year	?	Yes	[]	No
Old Cu	1 stodian	2 New Custodiar		3 Date of Change	4 Reas			
make investment decis	ions on behalf of the report	advisors, investment mana ting entity. For assets that a ounts"; "handle securities	are managed inte s"]					
Anthem Inc	1 Name of Firm or Individ	dual	2 Affiliation					
		able for Question 29.05, do and 10% of the reporting entity				Yes	[]	No
		reporting entity (i.e. designate to more than 50% of the				Yes	[]	No
For those firms or indiv the table below.	iduals listed in the table for	r 29.05 with an affiliation co	de of "A" (affiliate	ed) or "U" (unaffiliated), ր	provide the information for	or		
1		2		3	4		Inve	
Central Registration Depository Number	Name of	f Firm or Individual	Lea	al Entity Identifier (LEI)	Registered With	า	Agr	een
105377	Loomis, Sayles & Company,	LP	JIZPN	2RX3UMN0YIDI313	Securities Exchange Commission			
Does the reporting enti	ty have any diversified muti (SEC) in the Investment C	tual funds reported in Scheo Company Act of 1940 [Secti	dule D, Part 2 (div	versified according to the	e Securities and		[]	No
1			2				3 Adiust	ted
CUSIP#		Name	of Mutual Fund			Carryi		
Central Registration Depository Number		of Firm or Individual	JIZPN	al Entity Identifier (LEI)	Registered With Securities Exchange Commission		ı	Inve Mana Agr (IM/
	oming sorround.		2					
		Name				Book/	Adjust	
30.2999 - Total	•							_
For each mutual fund li	sted in the table above, cor	mplete the following schedu	ule:					
	1			2	3 Amount of Mutu Fund's Book/Adju		4	

1	2	3	4
		Amount of Mutual	I
		Fund's Book/Adjusted	I
		Carrying Value	I
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	27,016,024	26,993,471	(22,553)
31.2 Preferred stocks	0		0
31.3 Totals	27,016,024	26,993,471	(22,553)

31.4	Describe the sources or methods utilized in determining the fair values: Fair values were obtained from third-party pricing sources. If a security was not priced by a third-party pricing source, internal analytical systems or broker quotes were utilized.				
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes]	No	[X]
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes]	No	[]
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D: N/A				
	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes	[X]	No	[]
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. Has the reporting entity self-designated 5GI securities?	Yes	1	No	[X]
35.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. Has the reporting entity self-designated PLGI securities?	Yes	. 1	No	[X]
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Yes	: 1	No	[X]
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria? Yes [1 No.	ΙX	1 N/	1 Δ

GENERAL INTERROGATORIES

OTHER

	1 2 Amount Pai	d	
39.1	Amount of payments for legal expenses, if any?	\$	242,356
39.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal exduring the period covered by this statement.	penses	
	1 2 Name Amount Pai	id	
		8,418	
		5,072	
		ent if any? \$	9,494
40.1	Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of governments of governments.	сп., п апу:	
	Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of governments. List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures connection with matters before legislative bodies, officers or departments of government during the period covered by this state.	s in	
40.1 40.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures	s in ement.	

1	2
Name	Amount Paid
Preti Flaherty Beliveau Pachios LLP	8,235
Lobbying expenses disclosed reflect amounts reported in the Lobbyist Disclosure Reports filed with	i
the Secretary of State as well as the cost of external contractors who provided lobbying services to	
the Company. The amount may include expenses that may have been paid by an affiliate on behalf of the	i
Company and, as a result, may not be included in the Underwriting Gain reported on page 4 of the 2021	ì
Annual Statement.	

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1		ng entity have any direct Medicare Supplement Insurance in force?				
1.2	If yes, indicate premium earned on U.S. business only.					
1.3	What portion of Item (1.2) is not reported on the Medicare Supplement Insurance	\$				
	1.31 Reason for excluding					
	To the terror of the control of the terror o	and the latest the second Objective of	•			
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien					
1.5 1.6	Indicate total incurred claims on all Medicare Supplement Insurance	Most current three years:	\$			
1.0	individual policies.	1.61 Total premium earned	• 0			
		1.62 Total incurred claims				
		1.63 Number of covered lives				
		All years prior to most current three years:				
		1.64 Total premium earned				
		1.65 Total incurred claims				
		1.66 Number of covered lives				
1.7	Group policies:	Most current three years:				
		1.71 Total premium earned				
		1.72 Total incurred claims	\$0			
		1.73 Number of covered lives				
		All years prior to most current three years:				
		1.74 Total premium earned				
		1.75 Total incurred claims				
		1.76 Number of covered lives				
2.	Health Test:					
۷.	riediti i est.	1 2				
		Current Year Prior Year				
	2.1 Premium Numerator	76,123,555				
	2.2 Premium Denominator					
	2.3 Premium Ratio (2.1/2.2)					
	2.4 Reserve Numerator					
	2.5 Reserve Denominator					
	2.6 Reserve Ratio (2.4/2.5)	1.0001.000				
3.2	If yes, give particulars:					
4.1	Have copies of all agreements stating the period and nature of hospitals', physic dependents been filed with the appropriate regulatory agency?	clans , and dentists' care offered to subscribers and	Yes [X] No []			
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these	se agreements include additional benefits offered?	Yes [] No []			
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [] No [X]			
5.2	If no, explain: Anthem, Inc. will assume, pay, and discharge the obligations in the event the Co	ompany is insolvent.				
	-					
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical				
		5.32 Medical Only				
		5.33 Medicare Supplement				
		5.34 Dental & Vision				
		5.35 Other Limited Benefit Plan5.36 Other	\$			
6.	Describe arrangement which the reporting entity may have to protect subscribers hold harmless provisions, conversion privileges with other carriers, agreements	s and their dependents against the risk of insolvency including				
	agreements: Physician and hospital contracts contain provisions, including hold harmless agr insolvency.					
7.1	Does the reporting entity set up its claim liability for provider services on a service	ce date basis?	Yes [X] No []			
7.2	If no, give details					
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year 8.2 Number of providers at end of reporting year				
9.1	Does the reporting entity have business subject to premium rate guarantees?	, , ,				
J. I	boos the reporting entity have publicess subject to premium rate guardiffees?		.00 [] NO [A]			
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months	s \$			
۷.۲	you, a ou promium ournou.	9.22 Business with rate guarantees over 36 months				

GENERAL INTERROGATORIES

10.1	Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts?							No []
10.2	If yes:	10.21 Maximum amount payable bonuses				\$	2,333,004	
						thholds		
			10	7.24 Amount actua	iliy palu lol yeal wi	umolus	Φ	
11.1	Is the reporting entity organized as:							
					-	el,		No [X]
						ciation (IPA), or,		No [X]
				11.14 A MIXed	Model (combinatio	n of above)?	Yes []	No [X]
11.2	Is the reporting entity subject to Statutory Minimum (Capital and Surp	lus Requirements	?			Yes [X]	No []
11.3	If yes, show the name of the state requiring such min							Maine
11.4	If yes, show the amount required.							16,092,180
11.5	Is this amount included as part of a contingency rese	erve in stockholo	der's equity?				Yes []	No [X]
11.6	If the amount is calculated, show the calculation	tral Layel (2500/	* 2 572 202\					
	250% of Health Risk-Based Capital Authorized Con-	troi Levei (250%	3,572,382)					
12.	List service areas in which reporting entity is license	d to operate:						
			1 Name of Service	e Area				
	State of	Maine						
13.1	Do you act as a custodian for health savings accoun	its?					Yes []	No [X]
13.2	If yes, please provide the amount of custodial funds	held as of the re	porting date				\$	
13.3	Do you act as an administrator for health savings ac	counts?					Yes []	No [X]
13.4	If yes, please provide the balance of funds administe	ered as of the re	porting date				\$	
14.1	Are any of the captive affiliates reported on Schedul	e S, Part 3, auth	orized reinsurers?			Yes [1 No [] N/A [X]
14.2	If the answer to 14.1 is yes, please provide the follow						,	
	1	2	3	4	Assets	Supporting Reserv	e Credit	
		NAIC Company	Domiciliary	Reserve	5 Letters of	6 Trust	7	
	Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Other	
15.	Provide the following for individual ordinary life insur ceded):	ance* policies (l	J.S. business only) for the current yea	ar (prior to reinsura	ance assumed or		
	ocaca).			15.1 E	Direct Premium Wr	itten	\$	0
						ns		
				15.3 N	lumber of Covered	I Lives		0
		*Ordir	nary Life Insurance	Includes				
	Term(whether full und				app")			
	Whole Life (whether f	ull underwriting,	limited underwriting					
	Variable Life (with or		, ,					
	Universal Life (with or Variable Universal Life)			antee)				
16		,		,	o statos?		Yes [] No	. [Y]
16.	Is the reporting entity licensed or chartered, registered						igo [] INC	, [\]
16.1	If no, does the reporting entity assume reinsurance to domicile of the reporting entity?						Yes [] No	[X]

FIVE-YEAR HISTORICAL DATA

		1	2	3	4	5
		2021	2020	2019	2018	2017
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	113,783,409	54,566,885	6,715,354		
2.	Total liabilities (Page 3, Line 24)	83,041,704	40,465,057	360,286		
3.	Statutory minimum capital and surplus requirement	16,092,180	8,930,955	27,358		
4.	Total capital and surplus (Page 3, Line 33)	30,741,705	14,101,828	6,355,068		
	Income Statement (Page 4)					
5.	Total revenues (Line 8)	169,263,979	76,115,663	0		
6.	Total medical and hospital expenses (Line 18)	149,478,903	64,029,638	0		
7.	Claims adjustment expenses (Line 20)	8,378,491	2,903,480	0		
8.	Total administrative expenses (Line 21)	17,701,718	9,932,179	180,654		
9.	Net underwriting gain (loss) (Line 24)	(6,295,133)	(749,634)	(180,654)		
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)					
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	(676.319)	11.164.297	(180.426)		
	Risk-Based Capital Analysis	, , , ,	, , .	, ,		
14.	Total adjusted capital	30 741 705	14 101 828	6 355 068		
15.	Authorized control level risk-based capital					
10.	Enrollment (Exhibit 1)	, 202, 101	0,072,002			
16.	Total members at end of period (Column 5, Line 7)	14 152	7 646			
17.	Total members months (Column 6, Line 7)					
17.	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0	100,303				
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)			0.0		
20.	Cost containment expenses					
21.	Other claims adjustment expenses					
22.	Total underwriting deductions (Line 23)					
23.	Total underwriting gain (loss) (Line 24)	(3.7)	(1.0)	0.0		
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 13, Col. 5)	10,559,035				
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	12,792,387	0			
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)		0			
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)			0		
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)					
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)		0			
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31	3,936,356	2,238,256	0	0	
33.	Total investment in parent included in Lines 26 to					
	31 above. If a party to a merger, have the two most recent years	644			<u> </u>	

NOTE: If a party to a merger, have the two most recent years of this ex					
requirements of SSAP No. 3, Accounting Changes and Correction of Errors?]
If no, please explain:					

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

			1		Allocate	ed by States	and Territo	rect Business C	inly			
	States, etc.		Active Status	2 Accident and Health	Medicare	4 Medicaid	5 CHIP Title	6 Federal Employees Health Benefits Program	7 Life and Annuity Premiums & Other	Property/ Casualty	9 Total Columns 2	Deposit-Type
1.			(a) N	Premiums	Title XVIII	Title XIX	XXI	Premiums	Considerations	Premiums	Through 8	Contracts
		AL .									0	
	Alaska		N									
	Arizona		N	-				<u> </u>			0	
	Arkansas		N.								0	
		CA .	N								0	
		.00	N								0	
		CT .	N								0	
		DE .	N								0	
	District of Columbia . [-	N								0	
10.	Florida F	FL .	N								0	
11.	Georgia (GA .	N								0	
12.	Hawaii F	-H .	N								0	
13.	Idaho I	D.	N								0	
14.	Illinois I	L.	N								0	
15.	Indiana I	N .	N								0	
16.	lowa I	Α .	N								0	
	Kansas		N								0	
	Kentucky	-	N								0	
	Louisiana L		N					L			0	
		ME .	I		170.491.948			[170,491,948	
		MD .	N		175,751,070			Ī			170,431,340	
	Massachusetts		N					Ī			0	
			N								0	
	=	MI . MN .	N N.	-				<u> </u>			0	
	Mississippi		N					····			0	
		MO .	N					<u> </u>	}		0	
	Montana		N								0	
		NE .	N					····			0	
		NV .	N								0	
	New Hampshire N		N.								0	
	New Jersey		N								0	
32.	New Mexico	۱M .	N								0	
33.	New York	NY .	N								0	
34.	North Carolina N	NC .	N								0	
35.	North Dakota	ND .	N								0	
36.	Ohio (OH .	N								0	
37.	Oklahoma (OK .	N								0	
38.	Oregon (OR .	N								0	
	Pennsylvania F		N								0	
	Rhode Island F		N								0	
		sc .	N								0	
		SD .	N								0	
	Tennessee		N								0	
	Texas		N								0	
		JT .	N N		•			····			0	
		/T .	N N.					<u> </u>			0	
				-				 	<u> </u>			
	Virginia\		N								0	
	Washington		N					<u> </u>	}		0	
	West Virginia		N	-				····			0	
	Wisconsin		N	-				}	····		0	
		NY .	N	-				}	·		0	
	American Samoa		N								0	
	Guam (N					ļ	ļ		0	
	Puerto Rico F		N								0	
	U.S. Virgin Islands \	/I .	N.					ļ			0	
56.	Northern Mariana										_	
	Islands		N								0	
	Canada (CAN .	N.	-							0	
58.	Aggregate Other		V0.01		_	•		_		_	_	
	Aliens		XXX	0	0	0	0	0	0	0	0	
	Subtotal Reporting Entity Contributions for Emp	oloyee	XXX	0	170,491,948	0	0	0	0	0	170,491,948	
61	Benefit Plans		XXX	^	170 401 040		^	^		^	170 /01 0/8	
	Totals (Direct Business		XXX	0	170,491,948	0	0	0	0	0	170,491,948	
	DETAILS OF WRITE-I											
58001.			XXX					 				
58002.			XXX					 	 		+	
58003.	0		XXX					 	 			
	Summary of remaining write-ins for Line 58 fro overflow page	m	XXX	0	0	0	0	0	0	0	0	
	58003 plus 58998)(Lin											
	above)		XXX	0	0	0	0	0	0	0	0	

(a)	Active	Status	Counts:

R - Registered - Non-domiciled RRGs......0
Q - Qualified - Qualified or accredited reinsurer......0


⁽b) Explanation of basis of allocation by states, premiums by state, etc. Not applicable


BCBSA Licensee


Regulated Insurance Company


Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED










³ Wisconsin Collaborative Insurance Company is a joint venture 55% owned by Crossroads Acquisition Corp. and 45% owned by Aurora Health Care, Inc. (non-affiliate). Not consolidated for accounting purposes.

⁴ Anthem Workers' Compensation, LLC is owned 75% by Anthem Blue Cross Life and Health Insurance Company and 25% by HealthLink, Inc.



40.5


SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP PART 1 – ORGANIZATIONAL CHART


BCBSA Licensee

Regulated Insurance Company

Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED





G0 590


 $^{^{\}rm 6}$ Amerigroup Corporation holds a 2% interest in Highland Investor Holdings, LLC, and ATH Holding Company, LLC holds the remaining 98% interest.

 $^{^7}$ Alliance Care Management, LLC is 50% owned by Beacon Health Options, Inc. and 50% owned by Health Plus HP, LLC.

 $^{^8}$ TriaDD NY, LLC dba MyCompass is 25% owned by Alliance Care Management, LLC and the remaining 75% interest is owned by unaffiliated investors.

75% interest is owned by unaffiliated

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP PART 1 – ORGANIZATIONAL CHART




BCBSA Licensee


Regulated Insurance Company

Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



- 12 Community Care Health Plan of Louisiana, Inc. is a joint venture 75% owned by Anthem Partnership Holding Company, LLC and 25% owned by Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana (non-affiliata)
- ¹³ CCHA, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Colorado Community Health Alliance, LLC (non-affiliate)
- ¹⁴ AMH Health, LLC is a joint venture 50% owned by MaineHealth (non-affiliate) and 50% owned by Anthem Partnership Holding Company, LLC
- ¹⁵ Momentum Health Partners, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Blue Cross and Blue Shield of North Carolina (non-affiliate)
- ¹⁶ GR Health Solutions, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Independence Blue Cross, LLC (nonaffiliate)
- ¹⁷ Community Care Health Plan of Nebraska, Inc. is a joint venture 95% owned by Anthem Partnership Holding Company, LLC and 5% owned by Blue Cross and Blue Shield of Nebraska, Inc. (non-affiliate).
- ¹⁸ APC PASSE, LLC (regulated entity) is a joint venture 49% owned by Anthem Partnership Holding Company, LLC and 51% owned by Arkansas Provider Coalition, LLC (non-affiliate).
- ¹⁹ Community Care Health Plan of Kansas, Inc. is a joint venture 90% owned by Anthem Partnership Holding Company, LLC, 5% owned by Blue Cross and Blue Shield of Kansas (non-affiliate) and 5% owned by Blue Cross and Blue Shield of Kansas City (non-affiliate).



²¹ Other 50% owned by ACO del Norte, LLC (non-affiliate)

ANNUAL STATEMENT FOR THE YEAR 2021 OF THE AMH Health, LLC OVERFLOW PAGE FOR WRITE-INS

NONE